<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article" xml:lang="EN"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Mol Pharm</journal-id><journal-id journal-id-type="iso-abbrev">Mol. Pharm</journal-id><journal-id journal-id-type="publisher-id">mp</journal-id><journal-id journal-id-type="coden">mpohbp</journal-id><journal-title-group><journal-title>Molecular Pharmaceutics</journal-title></journal-title-group><issn pub-type="ppub">1543-8384</issn><issn pub-type="epub">1543-8392</issn><publisher><publisher-name>American Chemical
Society</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">25148225</article-id><article-id pub-id-type="pmc">4186676</article-id><article-id pub-id-type="doi">10.1021/mp500497p</article-id><article-categories><subj-group><subject>Article</subject></subj-group></article-categories><title-group><article-title>Development and Characterization of a Novel Mouse
Line Humanized for the Intestinal Peptide Transporter <italic>PEPT1</italic></article-title></title-group><contrib-group><contrib contrib-type="author" id="ath1"><name><surname>Hu</surname><given-names>Yongjun</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath2"><name><surname>Xie</surname><given-names>Yehua</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" id="ath3"><name><surname>Wang</surname><given-names>Yuqing</given-names></name><xref rid="aff2" ref-type="aff">&#x02021;</xref></contrib><contrib contrib-type="author" id="ath4"><name><surname>Chen</surname><given-names>Xiaomei</given-names></name><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><contrib contrib-type="author" corresp="yes" id="ath5"><name><surname>Smith</surname><given-names>David E.</given-names></name><xref rid="cor1" ref-type="other">*</xref><xref rid="aff1" ref-type="aff">&#x02020;</xref></contrib><aff id="aff1"><label>&#x02020;</label>Department
of Pharmaceutical Sciences, College of Pharmacy, <institution>University of Michigan</institution>, Ann Arbor, Michigan 48109, <country>United States</country></aff><aff id="aff2"><label>&#x02021;</label>College
of Pharmaceutical Sciences, <institution>Zhejiang University</institution>, Hangzhou 310058, <country>P. R. China</country></aff></contrib-group><author-notes><corresp id="cor1"><label>*</label>(D.E.S.) Tel: <phone>734-647-1431</phone> Fax: <fax>734-763-3438</fax>. E-mail: <email>smithb@umich.edu</email>.</corresp></author-notes><pub-date pub-type="pmc-release"><day>22</day><month>08</month><year>2015</year></pub-date><pub-date pub-type="epub"><day>22</day><month>08</month><year>2014</year></pub-date><pub-date pub-type="ppub"><day>06</day><month>10</month><year>2014</year></pub-date><volume>11</volume><issue>10</issue><fpage>3737</fpage><lpage>3746</lpage><history><date date-type="received"><day>22</day><month>07</month><year>2014</year></date><date date-type="accepted"><day>22</day><month>08</month><year>2014</year></date><date date-type="rev-recd"><day>15</day><month>08</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2014 American Chemical Society</copyright-statement><copyright-year>2014</copyright-year><copyright-holder>American Chemical Society</copyright-holder><license><license-p><ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="http://pubs.acs.org/page/policy/authorchoice_termsofuse.html">Terms of Use</ext-link></license-p></license></permissions><abstract><p content-type="toc-graphic"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0010" id="ab-tgr1"/></p><p>The
proton-coupled oligopeptide transporter PEPT1 (SLC15A1) is
abundantly expressed in the small intestine, but not colon, of mammals
and found to mediate the uptake of di/tripeptides and peptide-like
drugs from the intestinal lumen. However, species differences have
been observed in both the expression (and localization) of PEPT1 and
its substrate affinity. With this in mind, the objectives of this
study were to develop a humanized <italic>PEPT1</italic> mouse model
(<italic>huPEPT1</italic>) and to characterize hPEPT1 expression and
functional activity in the intestines. Thus, after generating <italic>huPEPT1</italic> mice in animals previously nulled for mouse <italic>Pept1</italic>, phenotypic, PCR, and immunoblot analyses were performed,
along with <italic>in situ</italic> single-pass intestinal perfusion
and <italic>in vivo</italic> oral pharmacokinetic studies with a model
dipeptide, glycylsarcosine (GlySar). Overall, the <italic>huPEPT1</italic> mice had normal survival rates, fertility, litter size, gender distribution,
and body weight. There was no obvious behavioral or pathological phenotype.
The mRNA and protein profiles indicated that <italic>huPEPT1</italic> mice had substantial PEPT1 expression in all regions of the small
intestine (i.e., duodenum, jejunum, and ileum) along with low but
measurable expression in both proximal and distal segments of the
colon. In agreement with PEPT1 expression, the <italic>in situ</italic> permeability of GlySar in <italic>huPEPT1</italic> mice was similar
to but lower than wildtype animals in small intestine, and greater
than wildtype mice in colon. However, a species difference existed
in the <italic>in situ</italic> transport kinetics of jejunal PEPT1,
in which the maximal flux and Michaelis constant of GlySar were reduced
7-fold and 2- to 4-fold, respectively, in <italic>huPEPT1</italic> compared to wildtype mice. Still, the <italic>in vivo</italic> function
of intestinal PEPT1 appeared fully restored (compared to <italic>Pept1</italic> knockout mice) as indicated by the nearly identical pharmacokinetics
and plasma concentration&#x02013;time profiles following a 5.0 nmol/g
oral dose of GlySar to <italic>huPEPT1</italic> and wildtype mice.
This study reports, for the first time, the development and characterization
of mice humanized for <italic>PEPT1</italic>. This novel transgenic <italic>huPEPT1</italic> mouse model should prove useful in examining the
role, relevance, and regulation of PEPT1 in diet and disease, and
in the drug discovery process.</p></abstract><kwd-group><kwd>PEPT1</kwd><kwd>humanized
mice</kwd><kwd>mRNA and protein expression</kwd><kwd>glycylsarcosine</kwd><kwd>in situ intestinal perfusions</kwd><kwd>in vivo oral pharmacokinetics</kwd></kwd-group><funding-group><funding-statement><funding-source>National Institutes of Health, United States</funding-source></funding-statement></funding-group><custom-meta-group><custom-meta><meta-name>document-id-old-9</meta-name><meta-value>mp500497p</meta-value></custom-meta><custom-meta><meta-name>document-id-new-14</meta-name><meta-value>mp-2014-00497p</meta-value></custom-meta><custom-meta><meta-name>ccc-price</meta-name><meta-value/></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="sec1"><title>Introduction</title><p>Mammalian PEPT1 (SLC15A1), along with
PEPT2 (SLC15A2), PHT1 (SLC15A4)
and PHT2 (SLC15A3), belong to the solute carrier group of membrane
transport proteins (i.e., SLC15) that mediate the cellular uptake
of di- and tripeptides in addition to several peptidomimetic drugs.
Following discovery of rabbit Pept1,<sup><xref ref-type="bibr" rid="ref1">1</xref></sup> the
human and mouse orthologues were cloned (85% amino acid identity)<sup><xref ref-type="bibr" rid="ref2">2</xref>,<xref ref-type="bibr" rid="ref3">3</xref></sup> in which they contained 708 and 709 amino acid residues, respectively.
These Pept1 transporters have 12 transmembrane domains, C- and N-termini
facing the cytoplasm, and Tyr12, His57, Tyr64, Trp294, Phe297, and
Glu595 residues located within highly conserved transmembrane domains
(H1, H2, H5, H7, and H10).<sup><xref ref-type="bibr" rid="ref4">4</xref></sup></p><p>In contrast
to PEPT2, a high-affinity low-capacity transporter
primarily responsible for the reabsorption of peptides/mimetics in
kidney,<sup><xref ref-type="bibr" rid="ref5">5</xref></sup> PEPT1 is a low-affinity high-capacity
transporter that is important in the absorption of digested peptides
(mostly di- and tripeptides) from dietary protein in the small intestine.
PEPT1 is also crucial for the intestinal uptake and absorption of
therapeutic drugs such as the &#x003b2;-lactam antibiotic cefadroxil<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> and the antiviral nucleoside prodrug valacyclovir.<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> Previous studies using polymerase chain reaction
(PCR) and immunoblot analyses have demonstrated that in rodents and
humans PEPT1 is abundantly expressed in the apical membrane of enterocytes
in duodenal, jejunal, and ileal regions.<sup><xref ref-type="bibr" rid="ref8">8</xref>&#x02212;<xref ref-type="bibr" rid="ref11">11</xref></sup> The expression of PEPT1 in colon
is controversial and perhaps species dependent. Nevertheless, under
normal conditions, PEPT1 is unlikely to have much impact on the absorption
of peptides/mimetics from this region.</p><p>Species differences in
PEPT1 expression and functional activity
have been reported in mouse and human colonic tissue.<sup><xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> Moreover, our laboratory demonstrated <italic>in vivo</italic> that
both cefadroxil<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> and valacyclovir<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> exhibited dose-proportional absorption in wildtype
and <italic>Pept1</italic> knockout mice after oral dose escalation.
The &#x0201c;apparent&#x0201d; dose linearity observed in these mouse
studies is contrary to the nonlinear intestinal absorption kinetics
reported in rats and humans for cefadroxil<sup><xref ref-type="bibr" rid="ref13">13</xref>,<xref ref-type="bibr" rid="ref14">14</xref></sup> and in humans for valacyclovir.<sup><xref ref-type="bibr" rid="ref15">15</xref></sup> Interspecies
differences in transporter-mediated activity are difficult to sort
out given that studies are usually performed by different investigators
and laboratories and especially under varying experimental conditions.
For this reason, we demonstrated in a single system, yeast <italic>Pichia pastoris</italic>, a species difference in the affinity of
glycylsarcosine (GlySar) for rat, mouse, and human PEPT1 transformants.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> These findings, and others, clearly illustrate
that species differences may impact the intestinal absorption and
pharmacokinetics of PEPT1 substrates, thereby, making it more difficult
to predict systemic drug exposure. It is also clear that cell culture
systems, naive or transfected with transporters of interest, as well
as further <italic>in vitro</italic> or <italic>in situ</italic> methods,
will not reflect what happens in humans under physiological conditions.</p><p>The past decade has shown a growing interest in the development
of humanized mice to overcome species differences in drug metabolism,
disposition, and regulation.<sup><xref ref-type="bibr" rid="ref17">17</xref>&#x02212;<xref ref-type="bibr" rid="ref21">21</xref></sup> Studies with humanized mouse models not only provide a mechanistic
understanding of species differences but also improve our ability
to optimize and predict the pharmacokinetic, therapeutic, and safety
profiles of xenobiotics in humans. With this in mind, the primary
aim of this study was to generate a humanized <italic>PEPT1</italic> (<italic>huPEPT1</italic>) mouse model, which was nulled for the
mouse <italic>Pept1</italic> gene and expresses the human transporter
in the tissues where <italic>Pept1</italic> is normally expressed.
The secondary aim was to characterize the <italic>huPEPT1</italic> mice with respect to hPEPT1 expression and functional activity in
the intestines, as examined by <italic>in situ</italic> permeability
and <italic>in vivo</italic> oral absorption studies with the model
dipeptide GlySar.</p></sec><sec id="sec2"><title>Experimental Section</title><sec id="sec2.1"><title>Chemicals</title><p>[<sup>3</sup>H]-GlySar (98 mCi/mmol), [<sup>14</sup>C]-GlySar (113 mCi/mmol),
and [<sup>14</sup>C]-inulin 5000
(1.1 mCi/g) were purchased from Moravek Biochemicals (Brea, CA). Unlabeled
GlySar and inulin 5000 were purchased from Sigma-Aldrich (St. Louis,
MO). Rabbit antihuman PEPT1 antiserum was generously provided by Dr.
Hannelore Daniel (Technische Universit&#x000e4;t M&#x000fc;nchen, Germany).
Protease inhibitor cocktail was purchased from Roche (Seattle, WA)
and Power SYBR Green PCR Master Mix from Applied Biosystems (Foster
City, CA). All other chemicals were obtained from standard sources.</p></sec><sec id="sec2.2"><title>Animals</title><p>Gender- and weight-matched mice (8 to 10 weeks)
were provided in-house for <italic>mPept1</italic><sup><italic>+/+</italic></sup> (wildtype), <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> (<italic>mPept1</italic> knockout), and <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup> (humanized or <italic>huPEPT1</italic>) genotypes. All animals were bred on a C57BL/6 background (&#x0003e;99%
congenic) in which the <italic>Pept1</italic> knockout and humanized
mice were identified by genotyping and culled from the same litters.
The mice were housed in a temperature-controlled environment with
12 h light and dark cycles and received a standard diet and water <italic>ad libitum</italic> (Unit for Laboratory Animal Medicine, University
of Michigan, Ann Arbor, MI). All mouse studies were performed in accordance
with the Guide for the Care and Use of Laboratory Animals as adopted
and promulgated by the U.S. National Institutes of Health.</p></sec><sec id="sec2.3"><title>Generation
and Molecular Characterization of Humanized <italic>PEPT1</italic> Mice</title><p><italic>huPEPT1</italic> mice were generated
using an approach described previously.<sup><xref ref-type="bibr" rid="ref22">22</xref></sup> In brief, bacterial artificial chromosomes (BACs) containing the <italic>PEPT1</italic> gene were obtained from a human BAC library (Empire
Genomics, Buffalo, NY). A BAC clone [RP11-782G13; &#x0223c;179 kb;
CHR13 (98,091,462&#x02013;98,270,723)], containing the entire 5&#x02032;-terminal
regulatory elements, coding area, and 3&#x02032;-terminal regulatory
elements, was then microinjected into the male pronucleus of fertilized
one-cell embryos obtained from <italic>Pept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> mice on a C57BL/6 background.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The pronuclear stage embryos were then transferred
into the uterus of pseudopregnant recipient animals. Founder mice
were screened to identify an animal containing one copy of the human
BAC after which these animals were bred (i.e., <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup> &#x000d7; <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> mice) to maintain hemizygous
transgenic lines.</p><p>Transgenic <italic>huPEPT1</italic> alleles
were detected in offspring by PCR using genomic DNA isolated from
tail biopsies. The first set had a forward primer 5&#x02032;-ATCTTCTTCATCGTGGTCAATG-3&#x02032;
and a reverse primer 5&#x02032;-CCCAGCTGATGAAATTTGTGAA-3&#x02032;,
with a product size of 200 bp. The second set had a forward primer
5&#x02032;-CCAATCTGCTCACACAGGATAGAGAGGGCAGG-3&#x02032; and a reverse
primer 5&#x02032;-CCTTGAGGCTGTCCAAGTGATTCAGGCCATCG-3&#x02032;,
with a product size of 524 bp. The endogenous <italic>mPept1</italic> gene was confirmed as nullified using a PCR approach described previously.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The PCR conditions were 1 cycle at 94 &#x000b0;C
for 2 min, 35 cycles at 94 &#x000b0;C for 30 s, 53 &#x000b0;C for 45 s,
and 72 &#x000b0;C for 60 s, and then 72 &#x000b0;C for 10 min.</p></sec><sec id="sec2.4"><title>Initial Phenotypic
Analysis</title><p>The <italic>huPEPT1</italic> mice were evaluated
for viability, fertility, serum clinical chemistry,
and histology, as performed previously for wildtype and <italic>Pept1</italic> knockout mice.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup></p></sec><sec id="sec2.5"><title>Real-time PCR and Immunoblot
Analyses</title><p>Quantitation
of <italic>hPEPT1</italic>, <italic>mPept1</italic>, <italic>mPept2</italic>, <italic>mPht1, mPht2</italic>, and other relevant genes was performed
in the small intestine, colon, and kidney of wildtype, m<italic>Pept1</italic> knockout, and humanized <italic>PEPT1</italic> mice using a 7300
Real-Time PCR system (Applied Biosystems, Foster City, CA) as described
before.<sup><xref ref-type="bibr" rid="ref24">24</xref></sup> In brief, 2.0 &#x003bc;g of total
RNA, isolated using the RNeasy Plus Mini Kit (Qiagen, Valencia, CA),
was reversely transcribed into cDNA using the Omniscript RT Kit (Qiagen,
Valencia, CA) with 16-mer random primers. The mouse <italic>Gapdh</italic> gene was used as an internal control of cDNA quality and quantity.
The primers (Table <xref rid="tbl1" ref-type="other">1</xref>) were designed using Primer
3.0 (Applied Biosystems, Foster City, CA) and synthesized by Integrated
DNA Technologies (Coraville, IA). The real-time PCR thermal conditions
were 1 cycle at 50 &#x000b0;C for 2 min, 1 cycle at 95 &#x000b0;C for 10
min, and then 40 cycles at 95 &#x000b0;C for 15 s and 60 &#x000b0;C for
1 min. The &#x00394;CT method was used to calculate the relative levels
of target gene transcripts in mice, where the ratio of target gene
to <italic>mGapdh</italic> was equal to 2<sup>&#x02013;&#x00394;CT</sup>, &#x00394;CT = CT(<italic>gene</italic>) &#x02013; CT (<italic>mGapdh</italic>).</p><table-wrap id="tbl1" position="float"><label>Table 1</label><caption><title>Primers Used in Quantitative Real
Time PCR</title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">gene<xref rid="t1fn1" ref-type="table-fn">a</xref></th><th style="border:none;" align="center">forward&#x000a0;primer&#x000a0;(5&#x02032;&#x02013;3&#x02032;)</th><th style="border:none;" align="center">reverse&#x000a0;primer&#x000a0;(5&#x02032;&#x02013;3&#x02032;)</th></tr></thead><tbody><tr><td style="border:none;" align="left">mGapdh (EC&#x000a0;=&#x000a0;1.2.1.12)</td><td style="border:none;" align="left">GAGACAGCCGCATCTTCTTGT</td><td style="border:none;" align="left">CACACCGACCTTCACCATTTT</td></tr><tr><td style="border:none;" align="left">hPEPT1
(SLC15A1)</td><td style="border:none;" align="left">TGACCTCACAGACCACAACCA</td><td style="border:none;" align="left">GCCAGGCCGATCAAGGA</td></tr><tr><td style="border:none;" align="left">mPept1 (Slc15a1)</td><td style="border:none;" align="left">CCACGGCCATTTACCATACG</td><td style="border:none;" align="left">TGCGATCAGAGCTCCAAGAA</td></tr><tr><td style="border:none;" align="left">mPept2 (Slc15a2)</td><td style="border:none;" align="left">TGCAGAGGCACGGACTAGATAC</td><td style="border:none;" align="left">GGGTGTGATGAACGTAGAAATCAA</td></tr><tr><td style="border:none;" align="left">mPht1
(Slc15a4)</td><td style="border:none;" align="left">GCTGCCACCTGCATTACTACTTC</td><td style="border:none;" align="left">CGTACTTCACAGACACAATGAGGAA</td></tr><tr><td style="border:none;" align="left">mPht2 (Slc15a3)</td><td style="border:none;" align="left">GCTGAAGCTTGCGTTCCAA</td><td style="border:none;" align="left">AACAGGTGGGCACTTTCAGAGT</td></tr><tr><td style="border:none;" align="left">mBphl (EC&#x000a0;=&#x000a0;3.1.-.-)</td><td style="border:none;" align="left">GCCAAGGTGGCTGTGAATG</td><td style="border:none;" align="left">GATCGCATGTTCCCCTTCTC</td></tr><tr><td style="border:none;" align="left">mAtb<sup>0,+</sup> (Slc6a14)</td><td style="border:none;" align="left">TCAGGATTTGACTTGGCATTCA</td><td style="border:none;" align="left">CAAGGCCCAATGTTAAAAGCA</td></tr><tr><td style="border:none;" align="left">mOat1
(Slc22a6)</td><td style="border:none;" align="left">CCACCTGCTAATGCCAACCT</td><td style="border:none;" align="left">GATTCGGGTCGTCCTTGCT</td></tr><tr><td style="border:none;" align="left">mOat2 (Slc22a7)</td><td style="border:none;" align="left">TGTCGCAAAGACCCTCGTACT</td><td style="border:none;" align="left">ACATCATCATGCAGCACAGTGA</td></tr><tr><td style="border:none;" align="left">mOat3
(Slc22a8)</td><td style="border:none;" align="left">GCCCCAGCCTCACTGTCTATAT</td><td style="border:none;" align="left">ACATTCAAGATAATGGTGCTCAGAGA</td></tr><tr><td style="border:none;" align="left">mOct1 (Slc22a1)</td><td style="border:none;" align="left">TGGTGTTCAGGCTGATGGAA</td><td style="border:none;" align="left">GCCCAAAACCCCAAACAAA</td></tr><tr><td style="border:none;" align="left">mMate1 (Slc47a1)</td><td style="border:none;" align="left">TTCTGCTTGTGACACGCTCAT</td><td style="border:none;" align="left">AGTGTCCCCCTTTGCAGGAT</td></tr><tr><td style="border:none;" align="left">mMate2
(Slc47a2)</td><td style="border:none;" align="left">GACATCATTTCCCTTGTGAGTCAA</td><td style="border:none;" align="left">GCCCGCAAGTGCATCAA</td></tr><tr><td style="border:none;" align="left">mPat1 (Slc36a1)</td><td style="border:none;" align="left">TCTGCTGTGTCTACTTCGTGTTTCT</td><td style="border:none;" align="left">GGATCACGGTCACATTGTTGTT</td></tr></tbody></table><table-wrap-foot><fn id="t1fn1"><label>a</label><p>Shown as gene name (<underline>s</underline>o<underline>l</underline>ute <underline>c</underline>arrier group
or <underline>e</underline>nzyme <underline>c</underline>ommission
number) for human (h) and mouse (m) transporters or enzymes.</p></fn></table-wrap-foot></table-wrap><p>Different segments of small intestine,
colon, and kidney of wildtype,
m<italic>Pept1</italic> knockout, and <italic>huPEPT1</italic> mice
were homogenized in 2.0 mL of Nonidet P40-lysis buffer (50 mM Tris-HCl,
150 mM NaCl, 1% Nonidet P40, and proteinase inhibitor cocktail, pH
8.0), as described previously for immunoblot analyses.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> The homogenates were sonicated for 10 pulses
in ice at half strength, and then centrifuged at 15,000<italic>g</italic> at 4 &#x000b0;C for 15 min. The final concentration of proteins was
measured with a BCA Protein Assay Kit (Pierce, Rockford, IL). The
proteins were denatured at 40 &#x000b0;C for 45 min, resolved using 10%
SDS-PAGE, transferred to a PVDF membrane (Millipore, Billerica, MA),
and then blotted with specific rabbit antihuman PEPT1 antiserum<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> (1:3000 dilution) or specific rabbit antimouse
PEPT1 antiserum<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> (1:5000 dilution).</p></sec><sec id="sec2.6"><title><italic>In Situ</italic> Single-Pass Intestinal Perfusion Studies</title><p>Wildtype, <italic>mPept1</italic> knockout, and humanized <italic>PEPT1</italic> mice were fasted overnight (&#x0223c;12 h), but with
free access to water, and anesthetized with sodium pentobarbital (40&#x02013;60
mg/kg intraperitoneal). The permeability of GlySar in regional segments
of the intestines (i.e., duodenum, jejunum, ileum, and colon) was
then determined simultaneously, as described previously.<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> In brief, the mouse was placed on top of a heating
pad to maintain body temperature, the abdominal area sterilized with
70% ethanol, and the intestine exposed by making an incision along
its midline. A 4 cm segment of duodenum, 8 cm segment of proximal
jejunum (&#x0223c;2 cm distal to the ligament of Treitz), 6 cm segment
of ileum (&#x0223c;1 cm proximal to the cecum), and 4 cm segment of
colon (&#x0223c;0.5 cm distal to the cecum) was isolated and followed
by incisions at both the proximal and distal ends. After the segment
was rinsed with 0.9% isotonic saline solution, a glass cannula (2.0
mm outer diameter) was inserted at each end of the intestinal segment
and secured in place with silk sutures. The isolated intestinal segment
was covered with saline-wetted gauze and parafilm to prevent dehydration.
After cannulation, the animals were then transferred to a temperature-controlled
chamber at 31 &#x000b0;C to maintain body temperature during the entire
perfusion procedure. The cannulas were then connected to inlet tubing
that was attached to a 30 mL syringe (BD, Franklin Lakes, NJ USA)
on a perfusion pump (Model 22: Harvard Apparatus, South Natick, MA)
and to outlet tubing that was placed in a collection vial.</p><p>The
perfusate buffer contained 135 mM NaCl, 5 mM KCl, and 10 mM MES/Tris
(pH 6.5), plus 10 &#x003bc;M [<sup>3</sup>H]-GlySar (0.5 &#x003bc;Ci)
and 0.01% (w/v) [<sup>14</sup>C]-inulin-5000 (0.25 &#x003bc;Ci), which
severed as a nonabsorbable marker to correct for water flux during
the perfusions. Buffer was perfused through each intestinal segment
at a flow rate of 0.1 mL/min, and the exiting perfusate was collected
every 10 min over a 90 min period. A 100 &#x003bc;L aliquot from each
collection was added to a vial containing 6.0 mL of scintillation
cocktail (Ecolite, MP Biochemicals, Solon, OH), and the samples were
measured for radioactivity by a dual-channel liquid scintillation
counter (Beckman LS 6000 SC, Beckman Coulter Inc., Fullerton, CA).
At the end of experimentation, the length of all four intestinal segments
was measured.</p><p>Concentration-dependent studies were also performed
in the jejunum
of wildtype and <italic>huPEPT1</italic> mice, by varying the perfusate
concentrations of GlySar over a wide range (0.01&#x02013;50 mM), to
assess its saturable transport kinetics.</p></sec><sec id="sec2.7"><title><italic>In Vivo</italic> Oral Pharmacokinetic Studies</title><p>Following an overnight fast
(&#x0223c;12 h), wildtype, <italic>mPept1</italic> knockout, and <italic>huPEPT1</italic> mice were anesthetized briefly
with isoflurane and administered 5.0 nmol/g [<sup>14</sup>C]-GlySar
(5.0 &#x003bc;Ci/mouse in 0.2 mL normal saline) orally by gavage. After
dosing, serial blood samples (15 &#x003bc;L) were collected at 5, 7.5,
15, 30, 45, 60, 90, 120, 180, 240, and 360 min via tail transections.
The blood samples were placed in tubes containing 1.0 &#x003bc;L of
EDTA-K3 and centrifuged at 3000<italic>g</italic> for 3 min to obtain
plasma (&#x0223c;5 &#x003bc;L). Animals were returned to their cages
between blood sampling where they had free access to water and, 2
h after dosing, food. Radioactivity in the plasma samples was measured
by a dual-channel liquid scintillation counter (Beckman LS 6000 SC,
Beckman Coulter Inc., Fullerton, CA).</p></sec><sec id="sec2.8"><title>Data Analysis</title><p>The steady-state loss of drug from perfusate
through the intestinal segments was achieved approximately 30 min
after the start of perfusion. The effective permeability (<italic>P</italic><sub>eff</sub>) of drug was calculated according to a complete
radial mixing parallel tube model:<sup><xref ref-type="bibr" rid="ref25">25</xref>,<xref ref-type="bibr" rid="ref26">26</xref></sup><disp-formula id="ueq1"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_m001" position="anchor"/></disp-formula>where <italic>Q</italic> is the perfusion
flow rate (0.1 mL/min), <italic>C</italic><sub>out</sub> is the outlet
GlySar concentration after water flux correction, C<sub><italic>in</italic></sub> is the inlet GlySar concentration, <italic>R</italic> is the
internal radius (0.1 cm for small intestine and 0.2 cm for colon),
and <italic>L</italic> is the length of intestinal segment.</p><p>The concentration-dependent flux (<italic>J</italic>) of GlySar in
jejunum was best fit to a single Michaelis&#x02013;Menten term in which<sup><xref ref-type="bibr" rid="ref12">12</xref></sup><disp-formula id="ueq2"><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_m002" position="anchor"/></disp-formula>where the parameters <italic>V</italic><sub>m</sub>&#x02032; and <italic>K</italic><sub>m</sub>&#x02032; were referenced
to the inlet concentrations (<italic>C</italic><sub>in</sub>) and
the parameters <italic>V</italic><sub>m</sub> and <italic>K</italic><sub>m</sub> were referenced to the intestinal wall concentrations
(<italic>C</italic><sub>w</sub>) after correcting for the unstirred
aqueous layer permeability.</p><p>Pharmacokinetic parameters, after
oral dosing of GlySar, were determined
using a noncompartmental approach (NCA, Phoenix WinNonlin v1.3, Certara,
St. Louis, MO).</p><p>Data were reported as mean &#x000b1; SE, unless
otherwise noted. Statistical
differences between two groups were determined by an unpaired <italic>t</italic> test. Multiple group comparisons were performed using
one-way analysis of variance (ANOVA) followed by Dunnett&#x02019;s
test in which wildtype mice served as the control group (GraphPad
Prism v5.0; GraphPad Software, Inc., La Jolla, CA). A value of <italic>p</italic> &#x0003c; 0.05 was considered significant.</p></sec></sec><sec sec-type="results" id="sec3"><title>Results</title><sec id="sec3.1"><title>Identification
of <italic>huPEPT1</italic> Mice</title><p>Mice
humanized for <italic>PEPT1</italic> were generated using a standard
microinjection transgenic strategy with BAC DNA such that the entire <italic>hPEPT1</italic> genome, comprising all regulatory and coding regions,
was integrated into the mouse chromosome for inheritance. As shown
in Figure <xref rid="fig1" ref-type="fig">1</xref>, PCR analysis of genomic DNA extracted
from tail biopsies demonstrated that <italic>hPEPT1</italic> genomic
DNA only appeared in <italic>huPEPT1</italic> (<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice and the BAC clone RP11-782G13,
which served as a positive control. In contrast, <italic>hPEPT1</italic> genomic DNA was not found in mouse genotypes <italic>mPept1</italic><sup><italic>+/+</italic></sup> (wildtype), <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> (<italic>mPept1</italic> knockout mice bred to hemizygous <italic>huPEPT1</italic> animals),
and <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> (m<italic>Pept1</italic> knockout mice not bred to hemizygous <italic>huPEPT1</italic> animals). Using wildtype primers, mouse <italic>Pept1</italic> genomic DNA was neither detected in <italic>huPEPT1</italic> nor <italic>Pept1</italic> knockout mice (i.e., the <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/huPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> and <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> genotypes). Since <italic>mPept1</italic> knockout primers were designed specifically to target
the <italic>Neo</italic> gene, inserted during homologous recombination
in the <italic>Pept1</italic> knockout mouse model,<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> a band was observed in <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>, <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/huPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>, and <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> mice, but not in <italic>mPept1</italic><sup><italic>+/+</italic></sup> animals.</p><fig id="fig1" position="float"><label>Figure 1</label><caption><p>Genotyping results for the identification of humanized <italic>PEPT1</italic> mice. Genomic DNA was extracted from mouse tail biopsies
and genotyped by PCR using specific primers, as described previously.<sup><xref ref-type="bibr" rid="ref23">23</xref></sup> The DNA ladder, consisting of 100 bp repeats,
was used to determine the size of PCR products. <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup> represents the positive screen
for humanized <italic>PEPT1</italic> (<italic>huPEPT1</italic>) mice, <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> the
negative screen for humanized <italic>PEPT1</italic> mice, <italic>mPept1</italic><sup><italic>+/+</italic></sup> the wildtype mice, <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup> the <italic>Pept1</italic> knockout (KO) mice, and RP11&#x02013;782G13 the purified
BAC DNA (used to inject fertilized eggs in generating <italic>huPEPT1</italic>), which serves as a positive control.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0002" id="gr1" position="float"/></fig><p>During the process of generating <italic>huPEPT1</italic> mice,
six founder mice were identified as containing the RP11-782G13 BAC
DNA for <italic>hPEPT1</italic>. However, only five of these mice
succeeded in germline transmission of the transgenic gene, and only
three mouse lines showed <italic>hPEPT1</italic> transcripts (data
not shown). The mouse line demonstrating the highest level of RNA
was bred and maintained for subsequent studies. Using real-time PCR,<sup><xref ref-type="bibr" rid="ref27">27</xref></sup> the integration copy number of BAC DNA transferred
from the RP11-782G13 clone was estimated as one in our humanized <italic>PEPT1</italic> mouse genome.</p></sec><sec id="sec3.2"><title>Initial Phenotypic Analysis</title><p>Hemizygous <italic>huPEPT1</italic> mice appeared normal with no
obvious behavioral abnormality as compared
to wildtype and <italic>mPept1</italic> knockout (<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>) mice. These humanized
mice had normal survival rates, fertility, litter size, gender distribution,
and body weight. Moreover, as shown in Table <xref rid="tbl2" ref-type="other">2</xref>, there were no significant differences in serum clinical chemistry
between the wildtype, <italic>Pept1</italic> knockout, and humanized <italic>PEPT1</italic> mice. Histologic evaluation (i.e., hematoxylin and
eosin staining) established normal morphology of the kidney, small
intestine, and cecum/colon across the three genetic strains (data
not shown).</p><table-wrap id="tbl2" position="float"><label>Table 2</label><caption><title>Serum Clinical Chemistry of Wildtype
(WT), Pept1 Knockout (KO), and Humanized PEPT1 (huPEPT1) Mice<xref rid="t2fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">&#x000a0;</th><th style="border:none;" align="center">WT</th><th style="border:none;" align="center">Pept1
KO</th><th style="border:none;" align="center">huPEPT1</th></tr></thead><tbody><tr><td colspan="4" style="border:none;" align="left">Body
Weight</td></tr><tr><td style="border:none;" align="left">male, 7&#x02013;8 weeks (g)</td><td style="border:none;" align="left">21.5&#x000a0;&#x000b1;&#x000a0;0.6 (12)</td><td style="border:none;" align="left">21.3&#x000a0;&#x000b1;&#x000a0;0.6 (12)</td><td style="border:none;" align="left">22.1&#x000a0;&#x000b1;&#x000a0;0.5 (12)</td></tr><tr><td style="border:none;" align="left">female, 7&#x02013;8 weeks (g)</td><td style="border:none;" align="left">17.9&#x000a0;&#x000b1;&#x000a0;0.3 (12)</td><td style="border:none;" align="left">17.7&#x000a0;&#x000b1;&#x000a0;0.4 (12)</td><td style="border:none;" align="left">18.0&#x000a0;&#x000b1;&#x000a0;0.3 (12)</td></tr><tr><td colspan="4" style="border:none;" align="left">Serum</td></tr><tr><td style="border:none;" align="left">sodium (mmol/L)</td><td style="border:none;" align="left">145&#x000a0;&#x000b1;&#x000a0;1 (6)</td><td style="border:none;" align="left">147&#x000a0;&#x000b1;&#x000a0;1 (6)</td><td style="border:none;" align="left">146&#x000a0;&#x000b1;&#x000a0;1 (6)</td></tr><tr><td style="border:none;" align="left">potassium (mmol/L)</td><td style="border:none;" align="left">7.3&#x000a0;&#x000b1;&#x000a0;0.5 (6)</td><td style="border:none;" align="left">7.4&#x000a0;&#x000b1;&#x000a0;0.3 (6)</td><td style="border:none;" align="left">7.7&#x000a0;&#x000b1;&#x000a0;0.5 (6)</td></tr><tr><td style="border:none;" align="left">chloride (mmol/L)</td><td style="border:none;" align="left">113&#x000a0;&#x000b1;&#x000a0;1 (6)</td><td style="border:none;" align="left">113&#x000a0;&#x000b1;&#x000a0;1 (6)</td><td style="border:none;" align="left">113&#x000a0;&#x000b1;&#x000a0;1 (6)</td></tr><tr><td style="border:none;" align="left">calcium (mg/dL)</td><td style="border:none;" align="left">9.7&#x000a0;&#x000b1;&#x000a0;0.5 (6)</td><td style="border:none;" align="left">9.5&#x000a0;&#x000b1;&#x000a0;0.1 (6)</td><td style="border:none;" align="left">9.8&#x000a0;&#x000b1;&#x000a0;0.2 (6)</td></tr><tr><td style="border:none;" align="left">albumin
(g/dL)</td><td style="border:none;" align="left">3.4&#x000a0;&#x000b1;&#x000a0;0.1 (6)</td><td style="border:none;" align="left">3.5&#x000a0;&#x000b1;&#x000a0;0.1 (6)</td><td style="border:none;" align="left">3.6&#x000a0;&#x000b1;&#x000a0;0.1 (6)</td></tr><tr><td style="border:none;" align="left">protein (g/dL)</td><td style="border:none;" align="left">6.4&#x000a0;&#x000b1;&#x000a0;0.1 (6)</td><td style="border:none;" align="left">6.4&#x000a0;&#x000b1;&#x000a0;0.1 (5)</td><td style="border:none;" align="left">6.3&#x000a0;&#x000b1;&#x000a0;0.1 (4)</td></tr><tr><td style="border:none;" align="left">creatinine (mg/dL)</td><td style="border:none;" align="left">0.24&#x000a0;&#x000b1;&#x000a0;0.03&#x000a0;(6)</td><td style="border:none;" align="left">0.25&#x000a0;&#x000b1;&#x000a0;0.01&#x000a0;(6)</td><td style="border:none;" align="left">0.28&#x000a0;&#x000b1;&#x000a0;0.05&#x000a0;(6)</td></tr><tr><td style="border:none;" align="left">bilirubin (mg/dL)</td><td style="border:none;" align="left">0.16&#x000a0;&#x000b1;&#x000a0;0.05 (5)</td><td style="border:none;" align="left">0.08&#x000a0;&#x000b1;&#x000a0;0.02 (5)</td><td style="border:none;" align="left">0.14&#x000a0;&#x000b1;&#x000a0;0.02 (5)</td></tr><tr><td style="border:none;" align="left">glucose (mg/dL)</td><td style="border:none;" align="left">131&#x000a0;&#x000b1;&#x000a0;22 (5)</td><td style="border:none;" align="left">163&#x000a0;&#x000b1;&#x000a0;18 (6)</td><td style="border:none;" align="left">188&#x000a0;&#x000b1;&#x000a0;6 (4)</td></tr><tr><td style="border:none;" align="left">BUN (mg/dL)</td><td style="border:none;" align="left">29.5&#x000a0;&#x000b1;&#x000a0;2.4 (6)</td><td style="border:none;" align="left">27.5&#x000a0;&#x000b1;&#x000a0;1.5 (6)</td><td style="border:none;" align="left">33.3&#x000a0;&#x000b1;&#x000a0;2.1 (6)</td></tr><tr><td style="border:none;" align="left">ALT (U/L)</td><td style="border:none;" align="left">95.2&#x000a0;&#x000b1;&#x000a0;16.0 (6)</td><td style="border:none;" align="left">78.0&#x000a0;&#x000b1;&#x000a0;4.8 (6)</td><td style="border:none;" align="left">101&#x000a0;&#x000b1;&#x000a0;6 (6)</td></tr><tr><td style="border:none;" align="left">ALP (U/L)</td><td style="border:none;" align="left">186&#x000a0;&#x000b1;&#x000a0;29&#x000a0;(6)</td><td style="border:none;" align="left">94.2&#x000a0;&#x000b1;&#x000a0;11.7&#x000a0;(6)</td><td style="border:none;" align="left">149&#x000a0;&#x000b1;&#x000a0;15&#x000a0;(6)</td></tr><tr><td style="border:none;" align="left">AST (U/L)</td><td style="border:none;" align="left">124&#x000a0;&#x000b1;&#x000a0;18 (6)</td><td style="border:none;" align="left">124&#x000a0;&#x000b1;&#x000a0;16 (6)</td><td style="border:none;" align="left">104&#x000a0;&#x000b1;&#x000a0;10 (6)</td></tr></tbody></table><table-wrap-foot><fn id="t2fn1"><label>a</label><p>Data are expressed
as mean &#x000b1;
SE (<italic>n</italic> = number of mice). <italic>Pept1</italic> KO
(<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>) and <italic>huPEPT1</italic> (<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice were not significantly different
than WT (<italic>mPept1</italic><sup><italic>+/+</italic></sup>) mice,
as evaluated by ANOVA/Dunnett&#x02019;s analyses. BUN is urea nitrogen,
ALT is alanine aminotransferase, ALP is alkaline phosphatase, and
AST is aspartate aminotransferase.</p></fn></table-wrap-foot></table-wrap></sec><sec id="sec3.3"><title>Stable Expression of hPEPT1 in the Intestine of Humanized Mice</title><p>Quantitative real-time PCR (qPCR) demonstrated that human (and
not mouse) <italic>PEPT1</italic> transcripts were expressed in the
small and large intestines of <italic>huPEPT1</italic> mice (Figure <xref rid="fig2" ref-type="fig">2</xref>A), but not in wildtype and <italic>Pept1</italic> knockout animals (data not shown). Moreover, mouse <italic>Pept1</italic> transcripts were expressed in wildtype animals but these same transcripts
were not observed in <italic>Pept1</italic> knockout mice (Figure <xref rid="fig2" ref-type="fig">2</xref>A). A comparison of <italic>Pept1</italic> expression
in proximal colon further demonstrated that <italic>hPEPT1</italic> mRNA was detectable in <italic>huPEPT1</italic> mice, whereas <italic>mPept1</italic> mRNA was not detectable in wildtype animals. Both <italic>hPEPT1</italic> and <italic>mPept1</italic> transcripts were observed
in the distal colon, respectively, of <italic>huPEPT1</italic> and
wildtype mice.</p><fig id="fig2" position="float"><label>Figure 2</label><caption><p>Real time-PCR analyses of <italic>mPept1</italic> or <italic>hPEPT1</italic> transcripts (A), <italic>mPept2</italic> transcripts
(B), <italic>mPht1</italic> transcripts (C), and <italic>mPht2</italic> transcripts
(D) in the small intestine, colon, and kidney of wildtype (WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> knockout (KO = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and humanized <italic>PEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice. Gene expression was
normalized by <italic>mGapdh</italic>. Duo represents the duodenum,
Jej the jejunum, Ile the ileum, PC the proximal colon, DC the distal
colon, and Kid the kidney. Data are expressed as mean &#x000b1; SE (<italic>n</italic> = 4&#x02013;6). *<italic>p</italic> &#x0003c; 0.05, **<italic>p</italic> &#x0003c; 0.01, and ***<italic>p</italic> &#x0003c; 0.001, as evaluated
by ANOVA/Dunnett&#x02019;s analyses in which WT was the control group.
Note the discontinuous <italic>y</italic>-axis in panels B&#x02013;D
and the different scaling compared to panel A.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0003" id="gr2" position="float"/></fig><p>Immunoblot analyses of intestine and kidney were performed
to assess
whether the <italic>hPEPT1</italic> transcripts would be translated
into protein. As observed in Figure <xref rid="fig3" ref-type="fig">3</xref>A, high
expression levels of hPEPT1 protein were noted in the duodenum, jejunum,
and ileum of humanized <italic>PEPT1</italic> mice. In contrast, <italic>huPEPT1</italic> animals had low expression of PEPT1 protein in the
proximal and distal colon, and no expression in kidney. Specificity
of the rabbit antihuman PEPT1 antibody was confirmed by the absence
of signal in jejunal samples from wildtype and <italic>Pept1</italic> knockout mice (Caco-2 cells served as a positive control). The presence
of mPEPT1 protein was also tested in mice using a specific rabbit
antimouse PEPT1 antibody, as shown in Figure <xref rid="fig3" ref-type="fig">3</xref>B. In agreement with the qPCR results, mouse PEPT1 protein was expressed
in the jejunum of wildtype mice, but not in the jejunum of <italic>huPEPT1</italic> and <italic>mPept1</italic> knockout animals (Caco-2
cells served as a negative control).</p><fig id="fig3" position="float"><label>Figure 3</label><caption><p>Immunoblots of hPEPT1 protein in the small
intestine, large intestine,
and kidney of wildtype (WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> knockout (KO = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and humanized <italic>PEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice (A), and mPEPT1 protein in the jejunum of the same genotypes
(B). Protein samples were separated by 10% SDS-PAGE, transferred onto
PVDF membranes, and incubated for 1.5 h with rabbit antihuman hPEPT1<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> (1:3000) or antimouse mPEPT1<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> (1:5000) antiserum, and a mouse monoclonal antibody for
&#x003b2;-actin (1:1000). The membranes were washed three times with
TBST and then incubated for 1 h with an appropriate secondary antibody
of IgG conjugated to horseradish peroxidase (1:3000). Caco-2 cells
served as positive and negative controls, respectively, for hPEPT1
and mPEPT1. Duo represents the duodenum, Jej the jejunum, Ile the
ileum, PC the proximal colon, DC the distal colon, and Kid the kidney.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0004" id="gr3" position="float"/></fig></sec><sec id="sec3.4"><title>Tissue Expression Profile
of Select Transporters and Enzymes</title><p>It is crucial to know
whether or not other proton-coupled oligopeptide
transporters (POTs) will be dysregulated as a compensatory response
to the mouse <italic>Pept1</italic> gene being replaced by a human <italic>PEPT1</italic> gene. As shown in Figure <xref rid="fig2" ref-type="fig">2</xref>B&#x02013;D,
qPCR analyses indicated little to no expression of mouse <italic>Pept2</italic>, <italic>Pht1</italic>, and <italic>Pht2</italic> transcripts in
the small and large intestines. There were moderate levels of <italic>mPept2</italic> mRNA in kidney; however, no change in expression
was observed between the three genotypes (Figure <xref rid="fig2" ref-type="fig">2</xref>B). In some cases, statistical differences were observed between
the other three POT family members (Figures <xref rid="fig2" ref-type="fig">2</xref>B&#x02013;D). Nevertheless, given their extremely low expression levels,
it is very unlikely that PEPT2 in the intestines and PHT1/2 in the
intestines and kidney will have meaningful protein expression.</p><p>The tissue expression of several relevant peptide/mimetic transporters
was also examined by qPCR. As shown in Figure <xref rid="fig4" ref-type="fig">4</xref>, only minor changes were observed in mouse mRNA expression of transporters
between the humanized <italic>PEPT1</italic> and <italic>mPept1</italic> knockout and wildtype animals. In this regard, m<italic>Pat1</italic> transcripts increased &#x0003c;2-fold in the small intestine of <italic>huPEPT1</italic> (compared to wildtype or knockout mice; Figure <xref rid="fig4" ref-type="fig">4</xref>A), <italic>mOat1</italic> transcripts increased
2-fold in the kidney of <italic>Pept1</italic> knockout mice (although
no difference was observed between wildtype and <italic>huPEPT1</italic> mice; Figure <xref rid="fig4" ref-type="fig">4</xref>C), and <italic>mOat2</italic> transcripts increased 2-fold in the kidney of <italic>huPEPT1</italic> mice (compared to wildtype or knockout mice; Figure <xref rid="fig4" ref-type="fig">4</xref>C). No differences were noted between the three genotypes
in mouse mRNA expression of <italic>mAtb</italic><sup><italic>0,+</italic></sup>, <italic>mOat3</italic>, <italic>mOct1</italic>, <italic>mMate1</italic>, and <italic>mMate2</italic> in the small and large intestines and
kidney.</p><fig id="fig4" position="float"><label>Figure 4</label><caption><p>Real time-PCR analyses of select transporters and enzymes in the
small intestine (A), large intestine (B), and kidney (C) of wildtype
(WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> knockout (KO = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and humanized <italic>PEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice. Refer to Table <xref rid="tbl1" ref-type="other">1</xref> for gene identification.
Data are expressed as mean &#x000b1; SE (<italic>n</italic> = 4&#x02013;6).
*<italic>p</italic> &#x0003c; 0.05 and **<italic>p</italic> &#x0003c; 0.01,
as evaluated by ANOVA/Dunnett&#x02019;s analyses in which WT was the
control group. Note the discontinuous <italic>y</italic>-axis in panel
A.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0005" id="gr4" position="float"/></fig><p>The biphenyl hydrolase-like enzyme
BPHL, important in activating
the prodrug valacyclovir to acyclovir, was evaluated in the intestines
and kidney by qPCR. A statistical decrease in mouse <italic>Bphl</italic> transcripts was observed in the small intestine of <italic>Pept1</italic> knockout mice (although no difference was observed between wildtype
and <italic>huPEPT1</italic> mice; Figure <xref rid="fig4" ref-type="fig">4</xref>A), and a statistical increase in mouse <italic>Bphl</italic> transcripts
was observed in the large intestine of <italic>huPEPT1</italic> mice
(compared to wildtype or knockout mice; Figure <xref rid="fig4" ref-type="fig">4</xref>B). It is very unlikely, however, that BPHL will have meaningful
protein expression in the intestines given their extremely low expression
levels. Finally, no difference in mouse <italic>Bphl</italic> transcripts
was observed between genotypes in the kidney (Figure <xref rid="fig4" ref-type="fig">4</xref>C).</p><p>Primers used in the qPCR analyses can be found in
Table <xref rid="tbl1" ref-type="other">1</xref>.</p></sec><sec id="sec3.5"><title><italic>In Situ</italic> Single-Pass Intestinal Perfusion Studies</title><p>Intestinal perfusion
studies were performed to evaluate the functional
activity of PEPT1 in different regions of the small and large intestines,
and to examine if differences exist between the three genotypes. As
shown in Figure <xref rid="fig5" ref-type="fig">5</xref>, there was substantial permeability
of GlySar in the duodenum, jejunum, and ileum of <italic>huPEPT1</italic> mice, although the permeability was lower than that observed in
wildtype animals. As expected, GlySar permeability was minimal, at
best, in <italic>Pept1</italic> knockout mice in all intestinal regions.
In agreement with the qPCR and immunoblot results, GlySar permeability
was low, but measurable, in the colon of <italic>huPEPT2</italic> mice
and about 11-fold higher than the colonic permeability observed in
wildtype animals.</p><fig id="fig5" position="float"><label>Figure 5</label><caption><p>Effective permeability of 10 &#x003bc;M [<sup>3</sup>H]-GlySar
in
different intestinal regions of wildtype (WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> knockout
(KO = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and humanized <italic>PEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice. All studies were performed
in pH 6.5 buffer. Data are expressed as mean &#x000b1; SE (<italic>n</italic> = 4&#x02013;6). **<italic>p</italic> &#x0003c; 0.01 and ***<italic>p</italic> &#x0003c; 0.001, as evaluated by ANOVA/Dunnett&#x02019;s analyses in which
WT was the control group.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0006" id="gr5" position="float"/></fig><p>To assess if there were species-dependent differences in
the transport
kinetics of GlySar by PEPT1, concentration-dependent perfusion studies
were performed in the jejunum of wildtype and <italic>huPEPT1</italic> mice. As shown in Figure <xref rid="fig6" ref-type="fig">6</xref>A, the maximal
flux (<italic>V</italic><sub>m</sub>&#x02032; = 3.75 &#x000b1; 0.11 nmol/cm<sup>2</sup>/sec for wildtype and 0.50 &#x000b1; 0.04 nmol/cm<sup>2</sup>/sec for <italic>huPEPT1</italic>) and Michaelis constant (<italic>K</italic><sub>m</sub>&#x02032; = 13.2 &#x000b1; 1.0 mM for wildtype
and 3.3 &#x000b1; 0.9 mM for <italic>huPEPT1</italic>) of GlySar were
substantially lower in mice humanized for the <italic>PEPT1</italic> gene. When intestinal wall concentrations were used as the reference,
after adjusting for the unstirred water layer, the maximal flux (<italic>V</italic><sub>m</sub> = 3.28 &#x000b1; 0.13 nmol/cm<sup>2</sup>/sec
for wildtype and 0.49 &#x000b1; 0.03 nmol/cm<sup>2</sup>/sec for <italic>huPEPT1</italic>) and Michaelis constant (<italic>K</italic><sub>m</sub> = 5.5 &#x000b1; 0.7 mM for wildtype and 2.7 &#x000b1; 0.6 mM for <italic>huPEPT1</italic>) were similarly lower in <italic>huPEPT1</italic> mice as compared to wildtype animals (Figure <xref rid="fig6" ref-type="fig">6</xref>B). These results demonstrate that a species difference exists in
the transport kinetics of intestinal PEPT1.</p><fig id="fig6" position="float"><label>Figure 6</label><caption><p>Concentration-dependent
flux of [<sup>3</sup>H]-GlySar (0.01&#x02013;50
mM total substrate) during jejunal perfusions of wildtype (WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>) and <italic>huPEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice. C<sub>in</sub> is the inlet concentration of GlySar in perfusate
in which <italic>V</italic><sub>m</sub>&#x02032; = 3.75 &#x000b1; 0.11
nmol/cm<sup>2</sup>/sec and <italic>K</italic><sub>m</sub>&#x02032;
= 13.2 &#x000b1; 1.0 mM for WT mice, <italic>r</italic><sup>2</sup> =
0.988; <italic>V</italic><sub>m</sub>&#x02032; = 0.50 &#x000b1; 0.04 nmol/cm<sup>2</sup>/sec and <italic>K</italic><sub>m</sub>&#x02032; = 3.3 &#x000b1;
0.9 mM for HU mice, <italic>r</italic><sup>2</sup> = 0.838 (A). <italic>C</italic><sub>w</sub> is the estimated concentration of GlySar at
the membrane wall in which <italic>V</italic><sub>m</sub> = 3.24 &#x000b1;
0.13 nmol/cm<sup>2</sup>/sec and <italic>K</italic><sub>m</sub> =
5.5 &#x000b1; 0.7 mM for WT mice, <italic>r</italic><sup>2</sup> = 0.993; <italic>V</italic><sub>m</sub> = 0.49 &#x000b1; 0.03 nmol/cm<sup>2</sup>/sec
and <italic>K</italic><sub>m</sub> = 2.7 &#x000b1; 0.6 mM for HU mice, <italic>r</italic><sup>2</sup> = 0.973 (B). All studies were performed in
pH 6.5 buffer. Data are expressed as mean &#x000b1; SE (<italic>n</italic> = 4&#x02013;6).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0007" id="gr6" position="float"/></fig></sec><sec id="sec3.6"><title><italic>In Vivo</italic> Oral Pharmacokinetic Studies</title><p>To assess the <italic>in vivo</italic> functional activity of <italic>hPEPT1</italic> in humanized mice,
the pharmacokinetics of the model
dipeptide GlySar was evaluated after oral dosing. As shown in Figure <xref rid="fig7" ref-type="fig">7</xref>, the plasma concentrations of GlySar were substantially
reduced in <italic>Pept1</italic> knockout mice, and according to
Table <xref rid="tbl3" ref-type="other">3</xref>, all pharmacokinetic parameters were
significantly different than wildtype animals. The systemic exposure
(AUC) of GlySar in <italic>Pept1</italic> knockout mice was about
50% of that observed in wildtype animals. In contrast, the plasma
concentration&#x02013;time profiles of GlySar in <italic>huPEPT1</italic> mice were virtually superimposable with that observed in wildtype
animals. Humanized <italic>PEPT1</italic> and wildtype mice had the
same values for <italic>C</italic><sub>max</sub> and <italic>T</italic><sub>max</sub>, suggesting that the absorption rate was not different
between the two genotypes. Moreover, the incremental AUC values (i.e.,
AUC<sub>0&#x02013;<italic>t</italic></sub>) in <italic>huPEPT1</italic> mice were 93%, 97%, and 104% of that in wildtype mice at 0.5, 2,
and 6 h, respectively, indicating that PEPT1 activity had been fully
restored in these mice.</p><fig id="fig7" position="float"><label>Figure 7</label><caption><p>Plasma concentration&#x02013;time profiles of
[<sup>14</sup>C]-GlySar
in wildtype (WT = <italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> knockout (KO = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and humanized <italic>PEPT1</italic> (HU = <italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice following a 5.0 nmol/g oral dose. Data are expressed as mean
&#x000b1; SE (<italic>n</italic> = 3) in which the <italic>y</italic>-axis is displayed on a linear scale (A) and on a logarithmic scale
(B).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="mp-2014-00497p_0008" id="gr7" position="float"/></fig><table-wrap id="tbl3" position="float"><label>Table 3</label><caption><title>Noncompartmental
Pharmacokinetics
of [<sup>14</sup>C]GlySar after a 5.0 nmol/g Oral Dose in Wildtype
(WT), Pept1 Knockout (KO), and Humanized PEPT1 (huPEPT1) Mice<xref rid="t3fn1" ref-type="table-fn">a</xref></title></caption><table frame="hsides" rules="groups" border="0"><colgroup><col align="left"/><col align="left"/><col align="left"/><col align="left"/></colgroup><thead><tr><th style="border:none;" align="center">parameter (units)</th><th style="border:none;" align="center">WT</th><th style="border:none;" align="center">Pept1 KO</th><th style="border:none;" align="center">huPEPT1</th></tr></thead><tbody><tr><td style="border:none;" align="left"><italic>C</italic><sub>max</sub> (&#x003bc;M)</td><td style="border:none;" align="left">2.71&#x000a0;&#x000b1;&#x000a0;0.09</td><td style="border:none;" align="left">1.27&#x000a0;&#x000b1;&#x000a0;0.05<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">2.86&#x000a0;&#x000b1;&#x000a0;0.09</td></tr><tr><td style="border:none;" align="left"><italic>T</italic><sub>max</sub> (h)</td><td style="border:none;" align="left">0.33&#x000a0;&#x000b1;&#x000a0;0.08</td><td style="border:none;" align="left">1.83&#x000a0;&#x000b1;&#x000a0;0.17<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">0.33&#x000a0;&#x000b1;&#x000a0;0.08</td></tr><tr><td style="border:none;" align="left">AUC<sub>0&#x02013;0.5</sub> (&#x003bc;M&#x000b7;h)</td><td style="border:none;" align="left">1.12&#x000a0;&#x000b1;&#x000a0;0.02</td><td style="border:none;" align="left">0.34&#x000a0;&#x000b1;&#x000a0;0.01<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">1.04&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td style="border:none;" align="left">AUC<sub>0&#x02013;2</sub> (&#x003bc;M&#x000b7;h)</td><td style="border:none;" align="left">4.76&#x000a0;&#x000b1;&#x000a0;0.12</td><td style="border:none;" align="left">2.04&#x000a0;&#x000b1;&#x000a0;0.04<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">4.61&#x000a0;&#x000b1;&#x000a0;0.04</td></tr><tr><td style="border:none;" align="left">AUC<sub>0&#x02013;6</sub> (&#x003bc;M&#x000b7;h)</td><td style="border:none;" align="left">11.6&#x000a0;&#x000b1;&#x000a0;0.6</td><td style="border:none;" align="left">6.66&#x000a0;&#x000b1;&#x000a0;0.25<xref rid="t3fn2" ref-type="table-fn">b</xref></td><td style="border:none;" align="left">12.1&#x000a0;&#x000b1;&#x000a0;0.3</td></tr></tbody></table><table-wrap-foot><fn id="t3fn1"><label>a</label><p>Data are expressed as mean &#x000b1;
SE (<italic>n</italic> = 3).</p></fn><fn id="t3fn2"><label>b</label><p>***<italic>P</italic> &#x0003c; 0.001,
as evaluated by ANOVA/Dunnett&#x02019;s analyses of WT (<italic>mPept1</italic><sup><italic>+/+</italic></sup>), <italic>Pept1</italic> KO (<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup>), and <italic>huPEPT1</italic> (<italic>mPept1</italic><sup><italic>&#x02013;/&#x02013;</italic></sup><italic>/hPEPT1</italic><sup><italic>+/&#x02013;</italic></sup>) mice, where WT was the control group.</p></fn></table-wrap-foot></table-wrap></sec></sec><sec sec-type="discussion" id="sec4"><title>Discussion</title><p>Substantial progress
has been made in generating and characterizing
mice that contain human CYP450 and conjugation enzymes<sup><xref ref-type="bibr" rid="ref19">19</xref>,<xref ref-type="bibr" rid="ref20">20</xref></sup> and nuclear receptors.<sup><xref ref-type="bibr" rid="ref20">20</xref>,<xref ref-type="bibr" rid="ref21">21</xref></sup> However, with the exception
of studies by Schinkel and co-workers<sup><xref ref-type="bibr" rid="ref28">28</xref>&#x02212;<xref ref-type="bibr" rid="ref30">30</xref></sup> in which several organic
anion-transporting polypeptide (OATP) transporters were humanized
in mice and Scheer et al.<sup><xref ref-type="bibr" rid="ref31">31</xref></sup> in which mice
were humanized for multidrug resistance-associated protein 2 (MRP2),
no other plasma membrane transporters have been humanized to date.
Thus, the ability to generate a <italic>huPEPT1</italic> mouse model
containing the entire human genome offers an unparalleled opportunity
to more reliably study <italic>in vivo</italic> systems in human PEPT1
absorption, transport, pharmacologic response, disease, and regulation.</p><p>In the present study, we developed and characterized a novel mouse
line humanized for <italic>PEPT1</italic>. In doing so, we made the
following observations: (1) <italic>huPEPT1</italic> mice had no obvious
behavioral or pathological phenotype; (2) mRNA and protein profiles
indicated that <italic>huPEPT1</italic> mice had substantial PEPT1
expression in all regions of the small intestine (i.e., duodenum,
jejunum, and ileum) along with low but measurable expression in both
proximal and distal segments of the colon; (3) the <italic>in situ</italic> permeability of GlySar in <italic>huPEPT1</italic> mice was similar
to but lower than wildtype animals in small intestine, and greater
than wildtype mice in colon; (4) a species difference existed in the <italic>in situ</italic> transport kinetics of jejunal PEPT1, in which the
maximal flux and Michaelis constant of GlySar were reduced in <italic>huPEPT1</italic> compared to wildtype mice; and (5) the <italic>in
vivo</italic> function of intestinal PEPT1 appeared fully restored
(compared to <italic>Pept1</italic> knockout mice) as indicated by
the nearly identical pharmacokinetics and plasma concentration&#x02013;time
profiles of GlySar in <italic>huPEPT1</italic> and wildtype mice following
a single oral dose.</p><p>There is good agreement among species (e.g.,
rat, mouse, and human)
regarding the abundant protein expression of PEPT1 in duodenal, jejunal,
and ileal segments of small intestine, and its apical localization.<sup><xref ref-type="bibr" rid="ref8">8</xref>&#x02212;<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref32">32</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> However, the colonic expression
of PEPT1 is controversial and may be the result of differences among
species, antibody specificity, regional specificity, and the methods
of preparation between different laboratories. Whereas some studies
have reported the expression of PEPT1 protein in normal mouse, rat,
and human colon,<sup><xref ref-type="bibr" rid="ref9">9</xref>,<xref ref-type="bibr" rid="ref11">11</xref>,<xref ref-type="bibr" rid="ref32">32</xref></sup> other studies have been unable to detect PEPT1 in normal colon.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref33">33</xref>&#x02212;<xref ref-type="bibr" rid="ref35">35</xref></sup> In particular,
Wuensch et al.<sup><xref ref-type="bibr" rid="ref11">11</xref></sup> found a distinct spatial
distribution of colonic PEPT1 in mice, rats, and humans in which immunostaining
was not observed in proximal colon, but significant staining was observed
in the distal colon. In our hands, we have consistently detected abundant
expression of PEPT1 protein in all regions of mouse and rat small
intestine, but not in the colon of rodents past 7 days of age.<sup><xref ref-type="bibr" rid="ref8">8</xref>,<xref ref-type="bibr" rid="ref12">12</xref></sup> In addition, the functional activity of mouse PEPT1 was consistent
with these expression levels, as determined by the permeability of
GlySar,<sup><xref ref-type="bibr" rid="ref12">12</xref></sup> cefadroxil,<sup><xref ref-type="bibr" rid="ref36">36</xref></sup> and valacyclovir<sup><xref ref-type="bibr" rid="ref37">37</xref></sup> in wildtype
compared to <italic>Pept1</italic> knockout mice. In the present study, <italic>huPEPT1</italic> mice had measurable expression of PEPT1 protein
in the distal and proximal colon (distal &#x0003e; proximal) and 11-fold
higher
permeabilities of GlySar in colon as compared to wildtype mice. Still,
the colonic permeability of GlySar was only about 25&#x02013;30% of
that in ileum. Therefore, it appears that <italic>huPEPT1</italic> mice (under regulatory control of the human genome) could express
a functional PEPT1 protein that transported GlySar across the colon,
whereas wildtype mice (under regulatory control of the murine genome)
did not have this capability.</p><p>A species-dependent difference
was also reported in the affinity
of PEPT1 for GlySar where the <italic>K</italic><sub>m</sub> values
varied over a 5.4-fold range in yeast <italic>Pichia pastoris</italic> expressing the human (0.86 mM), mouse (0.30 mM), and rat (0.16 mM)
transformants.<sup><xref ref-type="bibr" rid="ref16">16</xref></sup> In the present study,
this trend was reversed in which the <italic>K</italic><sub>m</sub> of GlySar was 2- to 4-fold lower (i.e., greater affinity), and the <italic>V</italic><sub>m</sub> or <italic>V</italic><sub>m</sub>&#x02032;
was 7-fold lower in <italic>huPEPT1</italic> mice compared to wildtype
animals during <italic>in situ</italic> jejunal perfusions of substrate.
It is unclear, at present, why the <italic>K</italic><sub>m</sub> values
of GlySar &#x0201c;flip-flop&#x0201d; when studied <italic>in vitro</italic> in yeast expressing PEPT1 mouse and human homologues compared to <italic>in situ</italic> during intestinal perfusions in wildtype and <italic>huPEPT1</italic> mice. Thus, it will be important to determine, in
subsequent studies, if the <italic>in vivo</italic> intestinal absorption
of GlySar (and other peptides/mimetics) is dose-dependent (nonlinear)
following oral dose escalation. In doing so, the <italic>huPEPT1</italic> mouse model might be useful in clarifying the discrepancy between
the dose-proportional absorption of cefadroxil<sup><xref ref-type="bibr" rid="ref6">6</xref></sup> and valacyclovir<sup><xref ref-type="bibr" rid="ref7">7</xref></sup> in mice over an 8-
to 10-fold oral dose range, respectively, and the nonlinear intestinal
absorption observed for these compounds in humans.<sup><xref ref-type="bibr" rid="ref14">14</xref>,<xref ref-type="bibr" rid="ref15">15</xref></sup> More important, perhaps, would be the ability of <italic>huPEPT1</italic> mice to better predict the oral drug (and prodrug) performance of
new chemical entities.</p><p>Previous studies have shown that, after
oral dosing, the <italic>in vivo</italic> systemic exposure of GlySar
in <italic>Pept1</italic> knockout mice was only about 50% of that
in wildtype mice even though <italic>in situ</italic> permeabilities
in the proximal small intestine differed
by &#x0003e;10-fold between genotypes.<sup><xref ref-type="bibr" rid="ref12">12</xref>,<xref ref-type="bibr" rid="ref39">39</xref></sup> To explain
this &#x0201c;apparent&#x0201d;
discrepancy, the authors suggested that GlySar may be able to take
advantage of the intestine&#x02019;s residual length and long residence
times so that passive absorption processes play a bigger role in the
absence of PEPT1. Our current study corroborated these earlier findings
where GlySar had a substantially reduced (&#x0003e;50-fold) <italic>in
situ</italic> permeability in the small intestine of <italic>Pept1</italic> knockout
mice but an <italic>in vivo</italic> oral availability that differed
by only 50%, compared to wildtype animals. Given the complexity of
intestinal absorption (including membrane permeability, luminal drug
concentration, and gastrointestinal residence time), it was not surprising
that the pharmacokinetics and oral absorption profiles of GlySar were
similar in wildtype and <italic>huPEPT1</italic> mice (Figure <xref rid="fig7" ref-type="fig">7</xref> and Table <xref rid="tbl3" ref-type="other">3</xref>), especially
when <italic>in situ</italic> permeabilities in the small intestine
of <italic>huPEPT1</italic> mice were reduced by only 30&#x02013;40%
and higher in colon (Figure <xref rid="fig5" ref-type="fig">5</xref>). However, since
species differences were observed in the transport kinetics (i.e., <italic>V</italic><sub>m</sub> and <italic>K</italic><sub>m</sub>) of GlySar,
it will be interesting to see whether or not the pharmacokinetics
are similar in wildtype and <italic>huPEPT1</italic> mice when higher
oral doses of substrate are administered and the chance of intestinal
PEPT1 saturability increases.</p><p>It should be appreciated that
transgenic mice were generated previously<sup><xref ref-type="bibr" rid="ref38">38</xref></sup> in which <italic>hPepT1</italic> expression
was regulated by the mouse &#x003b2;-actin or villin promoters as a
model for studying the role of PEPT1 in inflammatory bowel disease.
However, in these mice there was no deletion of endogenous mPEPT1.
As a result, the concomitant protein expression of mouse and human
PEPT1 in the intestines and other PEPT1-expressing tissues of the
body make it impossible to separate the role of each species-specific
transporter and, thereby, humanize the mouse. In our <italic>huPEPT1</italic> mouse model, the purified BAC DNA, containing the entire <italic>hPEPT1</italic> genome, was injected into eggs from <italic>Pept1</italic> knockout mice. As a result, the <italic>huPEPT1</italic> mice lacked
endogenous mPEPT1 protein and, by maintaining the mice as hemizygotes,
were able to avoid the potential interference of other endogenous
genes. Another advantage of using genomic DNA was that transcripts
of the <italic>huPEPT1</italic> gene were regulated by their own regulatory
elements and produced PEPT1 protein only if the gene translation mechanism
was conserved among mammals.</p><p>In concluding, the present study
reports, for the first time, the
development and initial characterization of <italic>huPEPT1</italic> mice. These mice are unique in that they contain a copy of the entire
human genome in mice previously nulled for <italic>mPept1</italic> and demonstrate the full restoration of PEPT1 function. There is
excellent agreement between hPEPT1 expression in the intestines, the <italic>in situ</italic> intestinal permeability of GlySar, and the <italic>in vivo</italic> intestinal absorption of GlySar following a single
oral dose. However, a clear species difference was observed in the
maximal flux and affinity of GlySar during <italic>in situ</italic> jejunal perfusions of <italic>huPEPT1</italic> mice as compared
to wildtype animals. These humanized <italic>PEPT1</italic> mice should
prove a valuable model in future studies investigating the role, relevance,
and regulation of PEPT1 in diet and disease and in the drug discovery
process.</p></sec></body><back><notes id="NOTES-d1558e2696-autogenerated" notes-type="conflict-of-interest"><p>The authors declare no
competing financial interest.</p></notes><ack><title>Acknowledgments</title><p>We greatly appreciate the expertise
of the Transgenic Animal
Model Core, University of Michigan, in helping us to generate the <italic>huPEPT1</italic> mice. This work was supported by Public Health Service
grant GM-035498 from the National Institute of General Medical Sciences
(to D.E.S.).</p></ack><ref-list><title>References</title><ref id="ref1"><mixed-citation publication-type="journal" id="cit1"><name><surname>Fei</surname><given-names>Y. J.</given-names></name>; <name><surname>Kanai</surname><given-names>Y.</given-names></name>; <name><surname>Nussberger</surname><given-names>S.</given-names></name>; <name><surname>Ganapathy</surname><given-names>V.</given-names></name>; <name><surname>Leibach</surname><given-names>F. H.</given-names></name>; <name><surname>Romero</surname><given-names>M. F.</given-names></name>; <name><surname>Singh</surname><given-names>S. K.</given-names></name>; <name><surname>Boron</surname><given-names>W. F.</given-names></name>; <name><surname>Hediger</surname><given-names>M. A.</given-names></name>
<article-title>Expression cloning of a mammalian
proton-coupled oligopeptide
transporter</article-title>. <source>Nature</source>
<year>1994</year>, <volume>368</volume>, <fpage>563</fpage>&#x02013;<lpage>566</lpage>.<pub-id pub-id-type="pmid">8139693</pub-id></mixed-citation></ref><ref id="ref2"><mixed-citation publication-type="journal" id="cit2"><name><surname>Liang</surname><given-names>R.</given-names></name>; <name><surname>Fei</surname><given-names>Y. J.</given-names></name>; <name><surname>Prasad</surname><given-names>P. D.</given-names></name>; <name><surname>Ramamoorthy</surname><given-names>S.</given-names></name>; <name><surname>Han</surname><given-names>H.</given-names></name>; <name><surname>Yang-Feng</surname><given-names>T. L.</given-names></name>; <name><surname>Hediger</surname><given-names>M. A.</given-names></name>; <name><surname>Ganapathy</surname><given-names>V.</given-names></name>; <name><surname>Leibach</surname><given-names>F. H.</given-names></name>
<article-title>Human intestinal H+/peptide cotransporter. Cloning,
functional expression, and chromosomal localization</article-title>. <source>J. Biol. Chem.</source>
<year>1995</year>, <volume>270</volume>, <fpage>6456</fpage>&#x02013;<lpage>6463</lpage>.<pub-id pub-id-type="pmid">7896779</pub-id></mixed-citation></ref><ref id="ref3"><mixed-citation publication-type="journal" id="cit3"><name><surname>Fei</surname><given-names>Y. J.</given-names></name>; <name><surname>Sugawara</surname><given-names>M.</given-names></name>; <name><surname>Liu</surname><given-names>J. C.</given-names></name>; <name><surname>Li</surname><given-names>H. W.</given-names></name>; <name><surname>Ganapathy</surname><given-names>V.</given-names></name>; <name><surname>Ganapathy</surname><given-names>M. E.</given-names></name>; <name><surname>Leibach</surname><given-names>F. H.</given-names></name>
<article-title>cDNA structure, genomic organization,
and promoter analysis of the mouse intestinal peptide transporter
PEPT1</article-title>. <source>Biochim. Biophys. Acta</source>
<year>2000</year>, <volume>1492</volume>, <fpage>145</fpage>&#x02013;<lpage>154</lpage>.<pub-id pub-id-type="pmid">11004485</pub-id></mixed-citation></ref><ref id="ref4"><mixed-citation publication-type="journal" id="cit4"><name><surname>Smith</surname><given-names>D. E.</given-names></name>; <name><surname>Clemencon</surname><given-names>B.</given-names></name>; <name><surname>Hediger</surname><given-names>M. A.</given-names></name>
<article-title>Proton-coupled oligopeptide transporter
family SLC15: physiological, pharmacological and pathological implications</article-title>. <source>Mol. Aspects Med.</source>
<year>2013</year>, <volume>34</volume>, <fpage>323</fpage>&#x02013;<lpage>336</lpage>.<pub-id pub-id-type="pmid">23506874</pub-id></mixed-citation></ref><ref id="ref5"><mixed-citation publication-type="journal" id="cit5"><name><surname>Ocheltree</surname><given-names>S. M.</given-names></name>; <name><surname>Shen</surname><given-names>H.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Keep</surname><given-names>R. F.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Role and
relevance of peptide transporter 2 (PEPT2) in the kidney and choroid
plexus: in vivo studies with glycylsarcosine in wild-type and PEPT2
knockout mice</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<year>2005</year>, <volume>315</volume>, <fpage>240</fpage>&#x02013;<lpage>247</lpage>.<pub-id pub-id-type="pmid">15987832</pub-id></mixed-citation></ref><ref id="ref6"><mixed-citation publication-type="journal" id="cit6"><name><surname>Posada</surname><given-names>M. M.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>In vivo absorption
and disposition of cefadroxil after
escalating oral doses in wild-type and PepT1 knockout mice</article-title>. <source>Pharm. Res.</source>
<year>2013</year>, <volume>30</volume>, <fpage>2931</fpage>&#x02013;<lpage>2939</lpage>.<pub-id pub-id-type="pmid">23959853</pub-id></mixed-citation></ref><ref id="ref7"><mixed-citation publication-type="journal" id="cit7"><name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Impact of peptide transporter 1 on the intestinal absorption
and pharmacokinetics of valacyclovir after oral dose escalation in
wild-type and PepT1 knockout mice</article-title>. <source>Drug Metab.
Dispos.</source>
<year>2013</year>, <volume>41</volume>, <fpage>1867</fpage>&#x02013;<lpage>1874</lpage>.<pub-id pub-id-type="pmid">23924683</pub-id></mixed-citation></ref><ref id="ref8"><mixed-citation publication-type="journal" id="cit8"><name><surname>Shen</surname><given-names>H.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>; <name><surname>Brosius</surname><given-names>F. C.</given-names><suffix>3rd.</suffix></name>
<article-title>Developmental
expression of PEPT1 and PEPT2 in rat small intestine, colon, and kidney</article-title>. <source>Pediatr. Res.</source>
<year>2001</year>, <volume>49</volume>, <fpage>789</fpage>&#x02013;<lpage>795</lpage>.<pub-id pub-id-type="pmid">11385139</pub-id></mixed-citation></ref><ref id="ref9"><mixed-citation publication-type="journal" id="cit9"><name><surname>Ziegler</surname><given-names>T. R.</given-names></name>; <name><surname>Fernandez-Estivariz</surname><given-names>C.</given-names></name>; <name><surname>Gu</surname><given-names>L. H.</given-names></name>; <name><surname>Bazargan</surname><given-names>N.</given-names></name>; <name><surname>Umeakunne</surname><given-names>K.</given-names></name>; <name><surname>Wallace</surname><given-names>T. M.</given-names></name>; <name><surname>Diaz</surname><given-names>E. E.</given-names></name>; <name><surname>Rosado</surname><given-names>K. E.</given-names></name>; <name><surname>Pascal</surname><given-names>R. R.</given-names></name>; <name><surname>Galloway</surname><given-names>J. R.</given-names></name>; <name><surname>Wilcox</surname><given-names>J. N.</given-names></name>; <name><surname>Leader</surname><given-names>L. M.</given-names></name>
<article-title>Distribution of
the H+/peptide transporter PepT1 in human intestine: up-regulated
expression in the colonic mucosa of patients with short-bowel syndrome</article-title>. <source>Am. J. Clin. Nutr.</source>
<year>2002</year>, <volume>75</volume>, <fpage>922</fpage>&#x02013;<lpage>930</lpage>.<pub-id pub-id-type="pmid">11976168</pub-id></mixed-citation></ref><ref id="ref10"><mixed-citation publication-type="journal" id="cit10"><name><surname>Walker</surname><given-names>D.</given-names></name>; <name><surname>Thwaites</surname><given-names>D. T.</given-names></name>; <name><surname>Simmons</surname><given-names>N. L.</given-names></name>; <name><surname>Gilbert</surname><given-names>H. J.</given-names></name>; <name><surname>Hirst</surname><given-names>B. H.</given-names></name>
<article-title>Substrate
upregulation of the human small intestinal peptide transporter, hPepT1</article-title>. <source>J. Physiol.</source>
<year>1998</year>, <volume>507</volume><issue>Pt 3</issue><fpage>697</fpage>&#x02013;<lpage>706</lpage>.<pub-id pub-id-type="pmid">9508831</pub-id></mixed-citation></ref><ref id="ref11"><mixed-citation publication-type="journal" id="cit11"><name><surname>Wuensch</surname><given-names>T.</given-names></name>; <name><surname>Schulz</surname><given-names>S.</given-names></name>; <name><surname>Ullrich</surname><given-names>S.</given-names></name>; <name><surname>Lill</surname><given-names>N.</given-names></name>; <name><surname>Stelzl</surname><given-names>T.</given-names></name>; <name><surname>Rubio-Aliaga</surname><given-names>I.</given-names></name>; <name><surname>Loh</surname><given-names>G.</given-names></name>; <name><surname>Chamaillard</surname><given-names>M.</given-names></name>; <name><surname>Haller</surname><given-names>D.</given-names></name>; <name><surname>Daniel</surname><given-names>H.</given-names></name>
<article-title>The peptide transporter PEPT1 is
expressed in distal colon in rodents and humans and contributes to
water absorption</article-title>. <source>Am. J. Physiol.: Gastrointest.
Liver Physiol.</source>
<year>2013</year>, <volume>305</volume>, <fpage>G66</fpage>&#x02013;<lpage>G73</lpage>.<pub-id pub-id-type="pmid">23660505</pub-id></mixed-citation></ref><ref id="ref12"><mixed-citation publication-type="journal" id="cit12"><name><surname>Jappar</surname><given-names>D.</given-names></name>; <name><surname>Wu</surname><given-names>S. P.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Significance and
regional dependency of peptide transporter (PEPT) 1 in the intestinal
permeability of glycylsarcosine: in situ single-pass perfusion studies
in wild-type and <italic>Pept1</italic> knockout mice</article-title>. <source>Drug Metab. Dispos.</source>
<year>2010</year>, <volume>38</volume>, <fpage>1740</fpage>&#x02013;<lpage>1746</lpage>.<pub-id pub-id-type="pmid">20660104</pub-id></mixed-citation></ref><ref id="ref13"><mixed-citation publication-type="journal" id="cit13"><name><surname>Sanchez-Pico</surname><given-names>A.</given-names></name>; <name><surname>Peris-Ribera</surname><given-names>J. E.</given-names></name>; <name><surname>Toledano</surname><given-names>C.</given-names></name>; <name><surname>Torres-Molina</surname><given-names>F.</given-names></name>; <name><surname>Casabo</surname><given-names>V. G.</given-names></name>; <name><surname>Martin-Villodre</surname><given-names>A.</given-names></name>; <name><surname>Pla-Delfina</surname><given-names>J. M.</given-names></name>
<article-title>Non-linear
intestinal absorption kinetics of cefadroxil in the rat</article-title>. <source>J. Pharm. Pharmacol.</source>
<year>1989</year>, <volume>41</volume>, <fpage>179</fpage>&#x02013;<lpage>185</lpage>.<pub-id pub-id-type="pmid">2568445</pub-id></mixed-citation></ref><ref id="ref14"><mixed-citation publication-type="journal" id="cit14"><name><surname>Garrigues</surname><given-names>T. M.</given-names></name>; <name><surname>Martin</surname><given-names>U.</given-names></name>; <name><surname>Peris-Ribera</surname><given-names>J. E.</given-names></name>; <name><surname>Prescott</surname><given-names>L. F.</given-names></name>
<article-title>Dose-dependent absorption
and elimination of cefadroxil in man</article-title>. <source>Eur. J.
Clin. Pharmacol.</source>
<year>1991</year>, <volume>41</volume>, <fpage>179</fpage>&#x02013;<lpage>183</lpage>.<pub-id pub-id-type="pmid">1743250</pub-id></mixed-citation></ref><ref id="ref15"><mixed-citation publication-type="journal" id="cit15"><name><surname>Weller</surname><given-names>S.</given-names></name>; <name><surname>Blum</surname><given-names>M. R.</given-names></name>; <name><surname>Doucette</surname><given-names>M.</given-names></name>; <name><surname>Burnette</surname><given-names>T.</given-names></name>; <name><surname>Cederberg</surname><given-names>D. M.</given-names></name>; <name><surname>de Miranda</surname><given-names>P.</given-names></name>; <name><surname>Smiley</surname><given-names>M. L.</given-names></name>
<article-title>Pharmacokinetics of the acyclovir
pro-drug valaciclovir after escalating single- and multiple-dose administration
to normal volunteers</article-title>. <source>Clin. Pharmacol. Ther.</source>
<year>1993</year>, <volume>54</volume>, <fpage>595</fpage>&#x02013;<lpage>605</lpage>.<pub-id pub-id-type="pmid">8275615</pub-id></mixed-citation></ref><ref id="ref16"><mixed-citation publication-type="journal" id="cit16"><name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Chen</surname><given-names>X.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Species-dependent
uptake of glycylsarcosine
but not oseltamivir in <italic>Pichia pastoris</italic> expressing
the rat, mouse, and human intestinal peptide transporter PEPT1</article-title>. <source>Drug Metab. Dispos.</source>
<year>2012</year>, <volume>40</volume>, <fpage>1328</fpage>&#x02013;<lpage>1335</lpage>.<pub-id pub-id-type="pmid">22490229</pub-id></mixed-citation></ref><ref id="ref17"><mixed-citation publication-type="journal" id="cit17"><name><surname>Cheung</surname><given-names>C.</given-names></name>; <name><surname>Gonzalez</surname><given-names>F. J.</given-names></name>
<article-title>Humanized mouse lines and their application for prediction
of human drug metabolism and toxicological risk assessment</article-title>. <source>J. Pharmacol. Exp. Ther.</source>
<year>2008</year>, <volume>327</volume>, <fpage>288</fpage>&#x02013;<lpage>299</lpage>.<pub-id pub-id-type="pmid">18682571</pub-id></mixed-citation></ref><ref id="ref18"><mixed-citation publication-type="journal" id="cit18"><name><surname>Stanley</surname><given-names>L. A.</given-names></name>; <name><surname>Horsburgh</surname><given-names>B. C.</given-names></name>; <name><surname>Ross</surname><given-names>J.</given-names></name>; <name><surname>Scheer</surname><given-names>N.</given-names></name>; <name><surname>Wolf</surname><given-names>C. R.</given-names></name>
<article-title>Drug transporters:
gatekeepers controlling access of xenobiotics to the cellular interior</article-title>. <source>Drug Metab. Rev.</source>
<year>2009</year>, <volume>41</volume>, <fpage>27</fpage>&#x02013;<lpage>65</lpage>.<pub-id pub-id-type="pmid">19514970</pub-id></mixed-citation></ref><ref id="ref19"><mixed-citation publication-type="journal" id="cit19"><name><surname>Jiang</surname><given-names>X. L.</given-names></name>; <name><surname>Gonzalez</surname><given-names>F. J.</given-names></name>; <name><surname>Yu</surname><given-names>A. M.</given-names></name>
<article-title>Drug-metabolizing enzyme, transporter,
and nuclear receptor genetically modified mouse models</article-title>. <source>Drug Metab. Rev.</source>
<year>2011</year>, <volume>43</volume>, <fpage>27</fpage>&#x02013;<lpage>40</lpage>.<pub-id pub-id-type="pmid">20854191</pub-id></mixed-citation></ref><ref id="ref20"><mixed-citation publication-type="journal" id="cit20"><name><surname>Boverhof</surname><given-names>D. R.</given-names></name>; <name><surname>Chamberlain</surname><given-names>M. P.</given-names></name>; <name><surname>Elcombe</surname><given-names>C. R.</given-names></name>; <name><surname>Gonzalez</surname><given-names>F. J.</given-names></name>; <name><surname>Heflich</surname><given-names>R. H.</given-names></name>; <name><surname>Hern&#x000e1;ndez</surname><given-names>L. G.</given-names></name>; <name><surname>Jacobs</surname><given-names>A. C.</given-names></name>; <name><surname>Jacobson-Kram</surname><given-names>D.</given-names></name>; <name><surname>Luijten</surname><given-names>M.</given-names></name>; <name><surname>Maggi</surname><given-names>A.</given-names></name>; <name><surname>Manjanatha</surname><given-names>M. G.</given-names></name>; <name><surname>Benthem</surname><given-names>J.</given-names></name>; <name><surname>Gollapudi</surname><given-names>B. B.</given-names></name>
<article-title>Transgenic animal models in toxicology:
historical perspectives and future outlook</article-title>. <source>Toxicol. Sci.</source>
<year>2011</year>, <volume>121</volume>, <fpage>207</fpage>&#x02013;<lpage>233</lpage>.<pub-id pub-id-type="pmid">21447610</pub-id></mixed-citation></ref><ref id="ref21"><mixed-citation publication-type="journal" id="cit21"><name><surname>Scheer</surname><given-names>N.</given-names></name>; <name><surname>Wolf</surname><given-names>C. R.</given-names></name>
<article-title>Xenobiotic receptor humanized mice and their utility</article-title>. <source>Drug Metab. Rev.</source>
<year>2013</year>, <volume>45</volume>, <fpage>110</fpage>&#x02013;<lpage>121</lpage>.<pub-id pub-id-type="pmid">23173549</pub-id></mixed-citation></ref><ref id="ref22"><mixed-citation publication-type="journal" id="cit22"><name><surname>Van
Keuren</surname><given-names>M. L.</given-names></name>; <name><surname>Gavrilina</surname><given-names>G. B.</given-names></name>; <name><surname>Filipiak</surname><given-names>W. E.</given-names></name>; <name><surname>Zeidler</surname><given-names>M. G.</given-names></name>; <name><surname>Saunders</surname><given-names>T. L.</given-names></name>
<article-title>Generating transgenic mice from bacterial artificial
chromosomes: transgenesis efficiency, integration and expression outcomes</article-title>. <source>Transgenic Res.</source>
<year>2009</year>, <volume>18</volume>, <fpage>769</fpage>&#x02013;<lpage>785</lpage>.<pub-id pub-id-type="pmid">19396621</pub-id></mixed-citation></ref><ref id="ref23"><mixed-citation publication-type="journal" id="cit23"><name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>; <name><surname>Ma</surname><given-names>K.</given-names></name>; <name><surname>Jappar</surname><given-names>D.</given-names></name>; <name><surname>Thomas</surname><given-names>W.</given-names></name>; <name><surname>Hillgren</surname><given-names>K. M.</given-names></name>
<article-title>Targeted disruption
of peptide transporter Pept1 gene
in mice significantly reduces dipeptide absorption in intestine</article-title>. <source>Mol. Pharmaceutics</source>
<year>2008</year>, <volume>5</volume>, <fpage>1122</fpage>&#x02013;<lpage>1130</lpage>.</mixed-citation></ref><ref id="ref24"><mixed-citation publication-type="journal" id="cit24"><name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Xie</surname><given-names>Y.</given-names></name>; <name><surname>Keep</surname><given-names>R. F.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Divergent developmental expression
and function of the proton-coupled oligopeptide transporters PepT2
and PhT1 in regional brain slices of mouse and rat</article-title>. <source>J. Neurochem.</source>
<year>2014</year>, <volume>129</volume>, <fpage>955</fpage>&#x02013;<lpage>965</lpage>.<pub-id pub-id-type="pmid">24548120</pub-id></mixed-citation></ref><ref id="ref25"><mixed-citation publication-type="journal" id="cit25"><name><surname>Kou</surname><given-names>J. H.</given-names></name>; <name><surname>Fleisher</surname><given-names>D.</given-names></name>; <name><surname>Amidon</surname><given-names>G. L.</given-names></name>
<article-title>Calculation of the aqueous diffusion
layer resistance for absorption in a tube: application to intestinal
membrane permeability determination</article-title>. <source>Pharm.
Res.</source>
<year>1991</year>, <volume>8</volume>, <fpage>298</fpage>&#x02013;<lpage>305</lpage>.<pub-id pub-id-type="pmid">2052515</pub-id></mixed-citation></ref><ref id="ref26"><mixed-citation publication-type="journal" id="cit26"><name><surname>Komiya</surname><given-names>I.</given-names></name>; <name><surname>Park</surname><given-names>J. Y.</given-names></name>; <name><surname>Kamani</surname><given-names>A.</given-names></name>; <name><surname>Ho</surname><given-names>N. F. H.</given-names></name>; <name><surname>Higuchi</surname><given-names>W. I.</given-names></name>
<article-title>Quantitative
mechanistic studies in simultaneous fluid flow and intestinal absorption
using steroids as model solutes</article-title>. <source>Int. J. Pharm.</source>
<year>1980</year>, <volume>4</volume>, <fpage>249</fpage>&#x02013;<lpage>262</lpage>.</mixed-citation></ref><ref id="ref27"><mixed-citation publication-type="journal" id="cit27"><name><surname>Chandler</surname><given-names>K. J.</given-names></name>; <name><surname>Chandler</surname><given-names>R. L.</given-names></name>; <name><surname>Broeckelmann</surname><given-names>E. M.</given-names></name>; <name><surname>Hou</surname><given-names>Y.</given-names></name>; <name><surname>Southard-Smith</surname><given-names>E. M.</given-names></name>; <name><surname>Mortlock</surname><given-names>D. P.</given-names></name>
<article-title>Relevance of BAC
transgene copy number in mice: transgene
copy number variation across multiple transgenic lines and correlations
with transgene integrity and expression</article-title>. <source>Mamm.
Genome</source>
<year>2007</year>, <volume>18</volume>, <fpage>693</fpage>&#x02013;<lpage>708</lpage>.<pub-id pub-id-type="pmid">17882484</pub-id></mixed-citation></ref><ref id="ref28"><mixed-citation publication-type="journal" id="cit28"><name><surname>van
de Steeg</surname><given-names>E.</given-names></name>; <name><surname>van der Kruijssen</surname><given-names>C.
M.</given-names></name>; <name><surname>Wagenaar</surname><given-names>E.</given-names></name>; <name><surname>Burggraaff</surname><given-names>J. E.</given-names></name>; <name><surname>Mesman</surname><given-names>E.</given-names></name>; <name><surname>Kenworthy</surname><given-names>K. E.</given-names></name>; <name><surname>Schinkel</surname><given-names>A. H.</given-names></name>
<article-title>Methotrexate pharmacokinetics in transgenic mice with
liver-specific expression of human organic anion-transporting polypeptide
1B1 (SLCO1B1)</article-title>. <source>Drug Metab. Dispos.</source>
<year>2009</year>, <volume>37</volume>, <fpage>277</fpage>&#x02013;<lpage>281</lpage>.<pub-id pub-id-type="pmid">19022939</pub-id></mixed-citation></ref><ref id="ref29"><mixed-citation publication-type="journal" id="cit29"><name><surname>van
de Steeg</surname><given-names>E.</given-names></name>; <name><surname>Str&#x000e1;neck&#x000fd;</surname><given-names>V.</given-names></name>; <name><surname>Hartmannov&#x000e1;</surname><given-names>H.</given-names></name>; <name><surname>Noskov&#x000e1;</surname><given-names>L.</given-names></name>; <name><surname>H&#x00159;eb&#x000ed;&#x0010d;ek</surname><given-names>M.</given-names></name>; <name><surname>Wagenaar</surname><given-names>E.</given-names></name>; <name><surname>van Esch</surname><given-names>A.</given-names></name>; <name><surname>de Waart</surname><given-names>D. R.</given-names></name>; <name><surname>Oude
Elferink</surname><given-names>R. P.</given-names></name>; <name><surname>Kenworthy</surname><given-names>K. E.</given-names></name>; <name><surname>Sticov&#x000e1;</surname><given-names>E.</given-names></name>; <name><surname>al-Edreesi</surname><given-names>M.</given-names></name>; <name><surname>Knisely</surname><given-names>A. S.</given-names></name>; <name><surname>Kmoch</surname><given-names>S.</given-names></name>; <name><surname>Jirsa</surname><given-names>M.</given-names></name>; <name><surname>Schinkel</surname><given-names>A. H.</given-names></name>
<article-title>Complete OATP1B1 and OATP1B3 deficiency causes human
Rotor syndrome by interrupting conjugated bilirubin reuptake into
the liver</article-title>. <source>J. Clin. Invest.</source>
<year>2012</year>, <volume>122</volume>, <fpage>519</fpage>&#x02013;<lpage>528</lpage>.<pub-id pub-id-type="pmid">22232210</pub-id></mixed-citation></ref><ref id="ref30"><mixed-citation publication-type="journal" id="cit30"><name><surname>van
de Steeg</surname><given-names>E.</given-names></name>; <name><surname>van Esch</surname><given-names>A.</given-names></name>; <name><surname>Wagenaar</surname><given-names>E.</given-names></name>; <name><surname>Kenworthy</surname><given-names>K. E.</given-names></name>; <name><surname>Schinkel</surname><given-names>A. H.</given-names></name>
<article-title>Influence of human OATP1B1, OATP1B3, and OATP1A2 on
the pharmacokinetics of methotrexate and paclitaxel in humanized transgenic
mice</article-title>. <source>Clin. Cancer Res.</source>
<year>2013</year>, <volume>19</volume>, <fpage>821</fpage>&#x02013;<lpage>832</lpage>.<pub-id pub-id-type="pmid">23243220</pub-id></mixed-citation></ref><ref id="ref31"><mixed-citation publication-type="journal" id="cit31"><name><surname>Scheer</surname><given-names>N.</given-names></name>; <name><surname>Balimane</surname><given-names>P.</given-names></name>; <name><surname>Hayward</surname><given-names>M. D.</given-names></name>; <name><surname>Buechel</surname><given-names>S.</given-names></name>; <name><surname>Kauselmann</surname><given-names>G.</given-names></name>; <name><surname>Wolf</surname><given-names>C. R.</given-names></name>
<article-title>Generation and characterization of
a novel multidrug
resistance protein 2 humanized mouse line</article-title>. <source>Drug
Metab. Dispos.</source>
<year>2012</year>, <volume>40</volume>, <fpage>2212</fpage>&#x02013;<lpage>2218</lpage>.<pub-id pub-id-type="pmid">22917771</pub-id></mixed-citation></ref><ref id="ref32"><mixed-citation publication-type="journal" id="cit32"><name><surname>Ford</surname><given-names>D.</given-names></name>; <name><surname>Howard</surname><given-names>A.</given-names></name>; <name><surname>Hirst</surname><given-names>B. H.</given-names></name>
<article-title>Expression of the peptide transporter
hPepT1 in human colon: a potential route for colonic protein nitrogen
and drug absorption</article-title>. <source>Histochem. Cell Biol.</source>
<year>2003</year>, <volume>119</volume>, <fpage>37</fpage>&#x02013;<lpage>43</lpage>.<pub-id pub-id-type="pmid">12548404</pub-id></mixed-citation></ref><ref id="ref33"><mixed-citation publication-type="journal" id="cit33"><name><surname>Ogihara</surname><given-names>H.</given-names></name>; <name><surname>Saito</surname><given-names>H.</given-names></name>; <name><surname>Shin</surname><given-names>B. C.</given-names></name>; <name><surname>Terado</surname><given-names>T.</given-names></name>; <name><surname>Takenoshita</surname><given-names>S.</given-names></name>; <name><surname>Nagamachi</surname><given-names>Y.</given-names></name>; <name><surname>Inui</surname><given-names>K.</given-names></name>; <name><surname>Takata</surname><given-names>K.</given-names></name>
<article-title>Immuno-localization
of H+/peptide cotransporter in rat digestive tract</article-title>. <source>Biochem. Biophys. Res. Commun.</source>
<year>1996</year>, <volume>220</volume>, <fpage>848</fpage>&#x02013;<lpage>852</lpage>.<pub-id pub-id-type="pmid">8607854</pub-id></mixed-citation></ref><ref id="ref34"><mixed-citation publication-type="journal" id="cit34"><name><surname>Groneberg</surname><given-names>D. A.</given-names></name>; <name><surname>Doring</surname><given-names>F.</given-names></name>; <name><surname>Eynott</surname><given-names>P. R.</given-names></name>; <name><surname>Fischer</surname><given-names>A.</given-names></name>; <name><surname>Daniel</surname><given-names>H.</given-names></name>
<article-title>Intestinal
peptide transport: ex vivo uptake studies and localization of peptide
carrier PEPT1</article-title>. <source>Am. J. Physiol.: Gastrointest.
Liver Physiol.</source>
<year>2001</year>, <volume>281</volume>, <fpage>G697</fpage>&#x02013;<lpage>G704</lpage>.<pub-id pub-id-type="pmid">11518682</pub-id></mixed-citation></ref><ref id="ref35"><mixed-citation publication-type="journal" id="cit35"><name><surname>Merlin</surname><given-names>D.</given-names></name>; <name><surname>Si-Tahar</surname><given-names>M.</given-names></name>; <name><surname>Sitaraman</surname><given-names>S. V.</given-names></name>; <name><surname>Eastburn</surname><given-names>K.</given-names></name>; <name><surname>Williams</surname><given-names>I.</given-names></name>; <name><surname>Liu</surname><given-names>X.</given-names></name>; <name><surname>Hediger</surname><given-names>M. A.</given-names></name>; <name><surname>Madara</surname><given-names>J. L.</given-names></name>
<article-title>Colonic epithelial hPepT1 expression
occurs in inflammatory bowel disease: transport of bacterial peptides
influences expression of MHC class 1 molecules</article-title>. <source>Gastroenterology</source>
<year>2001</year>, <volume>120</volume>, <fpage>1666</fpage>&#x02013;<lpage>1679</lpage>.<pub-id pub-id-type="pmid">11375948</pub-id></mixed-citation></ref><ref id="ref36"><mixed-citation publication-type="journal" id="cit36"><name><surname>Posada</surname><given-names>M. M.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Relevance of PepT1 in the intestinal permeability and
oral absorption of cefadroxil</article-title>. <source>Pharm. Res.</source>
<year>2013</year>, <volume>30</volume>, <fpage>1017</fpage>&#x02013;<lpage>1025</lpage>.<pub-id pub-id-type="pmid">23224978</pub-id></mixed-citation></ref><ref id="ref37"><mixed-citation publication-type="journal" id="cit37"><name><surname>Yang</surname><given-names>B.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Significance of
peptide transporter 1 in the intestinal
permeability of valacyclovir in wild-type and PepT1 knockout mice</article-title>. <source>Drug Metab. Dispos.</source>
<year>2013</year>, <volume>41</volume>, <fpage>608</fpage>&#x02013;<lpage>614</lpage>.<pub-id pub-id-type="pmid">23264448</pub-id></mixed-citation></ref><ref id="ref38"><mixed-citation publication-type="journal" id="cit38"><name><surname>Dalmasso</surname><given-names>G.</given-names></name>; <name><surname>Nguyen</surname><given-names>H. T.</given-names></name>; <name><surname>Ingersoll</surname><given-names>S. A.</given-names></name>; <name><surname>Ayyadurai</surname><given-names>S.</given-names></name>; <name><surname>Laroui</surname><given-names>H.</given-names></name>; <name><surname>Charania</surname><given-names>M. A.</given-names></name>; <name><surname>Yan</surname><given-names>Y.</given-names></name>; <name><surname>Sitaraman</surname><given-names>S. V.</given-names></name>; <name><surname>Merlin</surname><given-names>D.</given-names></name>
<article-title>The PepT1-NOD2 signaling pathway aggravates induced
colitis in mice</article-title>. <source>Gastroenterology</source>
<year>2011</year>, <volume>141</volume>, <fpage>1334</fpage>&#x02013;<lpage>1345</lpage>.<pub-id pub-id-type="pmid">21762661</pub-id></mixed-citation></ref><ref id="ref39"><mixed-citation publication-type="journal" id="cit39"><name><surname>Jappar</surname><given-names>D.</given-names></name>; <name><surname>Hu</surname><given-names>Y.</given-names></name>; <name><surname>Smith</surname><given-names>D. E.</given-names></name>
<article-title>Effect
of dose escalation on the in vivo oral absorption
and disposition of glycylsarcosine in wild-type and <italic>Pept1</italic> knockout mice</article-title>. <source>Drug Metab. Dispos.</source>
<year>2011</year>, <volume>39</volume>, <fpage>2250</fpage>&#x02013;<lpage>2257</lpage>.<pub-id pub-id-type="pmid">21880829</pub-id></mixed-citation></ref></ref-list></back></article>